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Abstract  
In the United States, more than 130,000 people will be diagnosed with colorectal cancer 
(CRC) each year and an estimated 50,000 people will die from the disease. Standard of care 
(SOC) therapies for CRC combine multiple cytotoxic chemotherapeutic drugs. These 
combinations have varying degrees of effectiveness and can often result in significant patient 
morbidity. For second recurrence patients, the multi-kinase inhibitor, regorafenib, is an approved 
agent, but is often poorly tolerated at current doses. In the current study, we propose to develop 
therapeutic regime of combining agents with modest toxicity profiles: curcumin and sildenafil 
with regorafenib. Using clinically achievable enterohepatic drug concentrations (~2.0 μM), our 
laboratory has shown that both sildenafil and curcumin interact to synergistically down regulate 
the expression of multiple cyto-protective molecular chaperones and kill CRC cells in a greater 
than additive manner in vitro and suppress the growth of colon cancer tumors in vivo. In this 
study, the expression of PDGFR and PDGF in the plasma was increased in colon tumor bearing 
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mice previously exposed to curcumin and sildenafil. Further, the in vitro killing potential of 
curcumin and sildenafil was shown to be reduced in evolved tumor cells from these mice.  
The purpose of this study was to determine whether down regulation of PDGFR using 
regorafenib would increase the lethality of curcumin and sildenafil in colorectal cancer cell lines 
in vitro and in vivo. In the current study, we have shown that with the [2μM curcumin + 2μM 
sildenafil + 2μM regorafenib] drug combination reduces of cyto-protective proteins, enhances 
cytotoxicity and creates a carnage of CRC cells in a greater than additive in vitro. The 
combination also suppressed growth of colon cancer tumors in vivo, when compared to curcumin 
and sildenafil alone. In addition we have shown that the [2μM curcumin + 2μM sildenafil + 2μM 
regorafenib] drug combination can modulate immune checkpoint proteins in vitro. These results 
suggest that this drug combination may enhanced the anti-tumor efficacy of anti-PD-1 and anti-
CTLA4 antibodies. 
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Introduction  
 
Colorectal Cancer 
Colon cancer is cancer of the large intestine, which is the final part of the digestive tract. 
Colorectal cancer (CRC) is the third most common cancer in the world, with about 1.4 million 
cases diagnosed worldwide in 2012.1,2,3 The prognosis for CRC patients is largely dependent on 
the stage of the tumor at diagnosis. In the United States, the 5-year survival rates following the 
surgical removal of tumors for localized (stage I), regional (stages II and III) and distant (stage 
IV) cases are 91.1, 71.7 and 13.3%, respectively.2,3 Thus, the mortality rates for each stage, 8–
13% (stage I/II), 11–47% (stage III) and approximately 89% (IV), represent the limitations of 
initial diagnoses and current treatments, indicating that more precise diagnostic measures and 
effective treatments are required.1,3 In most cases, colon cancer begin as small, benign clumps of 
cells called adenomatous polyps.1 On common occasions, polyps may produce few, if any, 
symptoms but can develop into malignant tumors. For this reason, doctors recommend regular 
screening tests to help prevent colon cancer by identifying and removing polyps before they 
develop into cancer.1 
The American Cancer Society’s estimates for the number of colorectal cancer cases in the 
United States for 2018 are 97,220 new cases of colon cancer 33,030 new cases of rectal cancer.1,2  
The risk of developing colorectal cancer is about 1 in 22 (3.39%) for men and 1 in 23 (3.15%) 
for women.1,2. A number of factors such as old age, race, family history, heavy alcohol 
consumption, smoking and high fat diets can increase the risk for developing colorectal cancer.2 
Colorectal cancer is expected to cause about 50,630 deaths during 2018. The death rate (the 
number of deaths per 50,000 people per year) from colorectal cancer has been dropping in both 
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men and women for several decades.2,3,4 There are a number of likely reasons for this. One, is 
that colorectal polyps are now being found more often by screening and removed before they can 
develop into cancers. The total funding for colorectal cancer research from the National Cancer 
Institute was 212.2 million dollars, or 3.1% of the total NCI budget in 2016 and is steadily 
increasing every year.3,4,7 
 
Treatments for Colorectal Cancer  
Current options for standard treatment of CRC include surgical removal for stage I and 
for most of stage II CRCs and adjuvant 5-fluoruracil (5-FU)-based chemotherapy for high-risk 
stage II and stage III CRCs. For metastatic stage IV disease, surgical removal of the primary 
CRC and/or metastatic lesions is followed by therapy using a variety of chemotherapy and 
targeted treatments.1,2,3 In addition, treatment for CRC has improved over the last few 
decades.2,3,4 As a result, there are now more than 1 million survivors of CRC in the United 
States. Overall, cancer death rates have declined 20% from their peak in 1991 (215.1 per 50,000 
population) to 2009 (173.1 per 50,000 population).2,3,5 
Surgery is the most common treatment for CRC that has not spread.5,6 A permanent 
colostomy, which is the creation of an abdominal opening for elimination of body waste, is a last 
resort when dealing for colon cancer and not usually required for rectal cancer. In combination 
with radiation for rectal cancer, patients are given chemotherapy before or after surgery to reduce 
tumors that have penetrated the bowel wall before there is metastasis.  For CRC that has spread 
to other parts of the body (metastatic colorectal cancer) a palliative care approach is another 
option.5,8  
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Chemotherapy is one of the foremost therapeutic interventions in cancer. Chemotherapy 
is a cancer treatment that uses drugs to stop the growth of cancer cells, either by killing the cells 
or by stopping them from dividing. When chemotherapy is taken by mouth or injected into a vein 
or muscle, the drugs enter the bloodstream and can reach cancer cells throughout the body. This 
is known as systemic chemotherapy. When chemotherapy is placed directly into a body cavity 
such as the abdomen, the drugs mainly affect cancer cells in those areas. This type of treatment is 
called regional chemotherapy.8 The way the chemotherapy is given depends on the type and 
stage of the cancer being treated. Chemotherapy is an important part of treatment for many 
people with CRC and doctors are constantly trying to make it more effective and safer.8 The use 
of chemotherapy drugs have been a relevant element in medicine. Moreover, there have been 
innovative ways in the approach to treat CRC. However, the use of plant alkaloids have normally 
been an afterthought in colon cancer treatment. The Dent lab has been implementing the drug 
combination technique with known drugs to work against CRC.9,10,11 For example, the use of 
curcumin along with sildenafil (Viagra) have shown optimistic results.9 However, advances in 
drug discovery and treatment protocols are still a work in progress as researchers are finding 
innovative ways to treat cancer. Nonetheless, efforts to increase the effectiveness of 
chemotherapy is still the number one priority.  
Targeted therapy drugs work differently from standard chemotherapy drugs. Targeted 
therapy is a type of treatment that uses drugs or other components to identify and attack specific 
cancer cells without harming normal cells. Types of targeted therapies used in the treatment of 
CRC used in this study include monoclonal antibodies. Monoclonal antibodies can identify target 
receptors on the cell surface of cancer cells. The antibodies attach to specific receptors resulting 
in cancer cell death, reduction in cancer cell growth, or a reduction in metastasis. Monoclonal 
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antibodies are given by infusion. They may be used alone or to carry drugs, toxins, or radioactive 
material directly to cancer cells.8  
In the current study we use a specific multi-kinase inhibitor to treat CRC called 
regorafenib. This drug used to treat CRC that has metastasized and proved resistant to previous 
therapy.12 Regorafenib blocks the action of certain proteins, including vascular endothelial 
growth factor (VEGF). This may help keep cancer cells from growing and potentially lead to 
programmed cell death. It may also prevent the growth of new blood vessels that tumors need to 
grow.13,14,15In this lab, we have determined that sorafenib or its derivate regorafenib interacts 
with sildenafil to kill tumor cell.10 Studies have shown that this type of therapy remains 
extremely challenging because of the chance of a resurgence of cancer due to survival enhancing 
mutational events. For example, this lab conducted experimental treatments of gastrointestinal 
cancers with curcumin and sildenafil. After running a multiplex analyses of mouse plasma and 
tumor samples taken after drug exposure, in vivo surviving tumors were shown to express 
platelet derived growth factor beta (PDGFRβ), which may represent a survival signal for these 
evolved cells. Regorafenib was used in the current study as a means to down regulate the 
PDGFRβ and so enhance the tumor cell killing potential of curcumin and sildenafil.11 
Previous studies in our laboratory have shown that curcumin and sildenafil can modulate 
the cell surface expression of a number of check point proteins and can be exploited to enhance 
immunotherapeutic tumor cell death.  Immunotherapy is a treatment that uses the patient's 
immune system to fight cancer. Substances made by the body or made in a laboratory are used to 
boost, direct, or restore the body's natural defenses against cancer. This type of cancer treatment 
is also called biotherapy or biologic therapy.7 Past studies in the Dent lab have shown that 
experimenting on immunogenicity can prove to treat colorectal cancer.16,17 In this study, the 
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focus is on a number of immune markers such as PDL-1 and MHCA1. PDL-1 is a protein on the 
surface of cancer cells. When PD-1 on the cell surface of T cells attaches to PDL-1 on the cell 
surface of a cancer cell, the potential of the T cell to recognize and initiate an immune response, 
potentially leading to cancer cell death, is neutralized. PD-1 inhibitors such as PD-1 antibodies 
attach to the PD-1 receptor on the cell surface of T cells, preventing the PD-1 from binding to the 
PDL-1 on the surface of cancer cells. This in turn prevents T cell neutralization and allowing the 
T cells to recognize the cancer cell without being inactivated and so can potentially kill cancer 
cells.8,16,17,18 MHCA1 complexes are presented on nucleated cells and are recognized by 
cytotoxic CD8+ T cells. Once CD8+ T cells recognize the cell as either foreign or ill, they induce 
cell death.19,20 
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Curcumin 
This study involves the use of curcumin to induce cell death in colon cancer cells. 
Curcumin is a yellow pigment from Curcuma longa, is a major component of turmeric and is 
commonly used as a spice and food-coloring agent. 11,21,23,24,25,26 Curcumin is a low-molecular-
weight polyphenol, first chemically characterized in 1915, with the molecular formula of 
C21H20O6  (Figure 1). It is generally regarded as a very active constituent and is comprises 2–
8% of most turmeric preparations.27 It has long been incorporated as the yellow spice in the 
India subcontinent diet for centuries and reviews have claimed colorectal cancer rates are much 
lower in India compared to other places in the world.13,28 Curcumin has been used as a 
treatment of inflammatory diseases for hundreds of years.11,15,23 Moreover, it is also used as a 
cosmetic and in some medical preparations.11,21,23,24,25,26,54 It is worthwhile to outline its role in 
the creation of free radicals and its potent antioxidant abilities in health and disease.11,21,29,30,47 
Because of the free radical-mediated peroxidation of membrane lipids and oxidative damage of 
DNA and proteins, curcumin is believed to play a therapeutic role in a variety of chronic 
pathological complications such as cancer, atherosclerosis, neurodegenerative 
diseases.11,21,23,25,31 Hence, the past few decades have witnessed intense research devoted to the 
antioxidant activity of curcumin.11,21,23,24,30,31,33,34,44 It also exhibits antitumor 
properties.11,21,23,25,30,33 Curcumin has been known to modulate many signal transduction events 
including those involving MAPK, PDGF FGF, EGF, VEGFR, c-KIT pathways as well as up-
regulation and down-regulation of specific genes.11,22,26,31,35,36,37,38,39 For example; curcumin 
inhibits the activity of histone deacetylases (HDACs), suppresses the activation of transcription 
factor NF-κB/AP-1 signaling and increases reactive oxygen species (ROS), which in turn causes 
endoplasmic reticular stress.11,36,37,38,39,46 In Paul Dent’s laboratory, it has been shown that 
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curcumin has potent and reactive effects on autophagy, apoptosis, endoplasmic reticulum 
proteins, and histone deacetylase inhibitors.11,30,31 Curcumin usually does not cause significant 
side effects but research has shown that some people have experienced upset stomachs, 
nausea, dizziness, diarrhea, increased bleeding at very at high doses surpassing 1500 
milligrams more than once a daily. High doses can also lead to abnormal heartbeat.40,41,42 
Studies have shown that the uptake of curcumin isn’t as high but is very achievable in the body 
at 2μM.11 In this study, the main focus was whether regorafenib is able to enhance the cell 
killing potential of curcumin and sildenafil. Curcumin’s cost and availability also makes it a 
forerunner to use in treatment. For this reason, curcumin is used in tis combinational drug 
study.109  
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Figure 1. Chemical Structure of Curcumin106 
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Sildenafil Citrate 
In this study, we combined curcumin with sildenafil. In our laboratory, we have shown 
that sildenafil can enhance the cell killing potential of a number of FDA approved 
chemotherapeutics. Sildenafil Citrate (also known as Revatio or Viagra), (Figure 2), was released 
to the public in 1998 after FDA approval as an oral treatment for heart related illnesses but it was 
later realized that it aids in erectile dysfunction.11,48-53 More specifically, Viagra is used for its 
cardio-protectiveness in many cardiovascular conditions such as heart failure, coronary artery 
disease, hypertension and heart transplantation.11,48-53 Sildenafil also acts by inhibiting cGMP-
specific phosphodiesterase type 5 (PDE5), an enzyme that promotes degradation of cGMP.11,48-53 
PDE5 is overexpressed in several types of human carcinoma including colorectal, genitourinary 
and liver cancer.54, 62 In Dent’s laboratory, studies have shown the effectiveness of sildenafil on 
tumor cells.11,48-53 The PDE5 inhibitor is also known to increase reactive nitrogen species (RNS) 
at a very significant level. 11,12,51 PDE5 inhibitors elevate cGMP levels which in turns elevates 
expression of nitric oxide synthase (NOS) enzymes, particularly endothelial NOS (eNOS) and 
inducible NOS (iNOS), activating protein kinase C (PKC) isoforms and protein kinase G (PKG). 
This ultimately leads to the inactivity of DNA, proteins, and lipids and activates apoptosis and 
the activity of caspases via forming the toxic oxidant peroxy-nitrite (ONOO-).11,12,51 Clinical side 
effects of Viagra have been more severe with increased dosage.56 The side effects include 
flushing, headaches, nasal congestion, painful erections, heart burn, and lightheadedness.11,56,57,69 
Other studies, including ones out of the Dent laboratory have noted the effect on intracellular 
pathways such as the Mitogen Active Protein Kinase (MAPK) pathway and the c-Jun N-terminal 
kinases (JNK) pathway.60 In the context of this study, sildenafil is used for its anti-cancer 
properties as well as it readily availability and cost. 11,12,48-53,58  
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Figure 2. Chemical Structure of Sildenafil107 
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Regorafenib 
In the study previous to this, the evolved tumor cells from curcumin and sildenafil treated 
mice where shown to over express PDGFR. The over expression of PDGFR may act as a 
survival signal to these tumor cells and may represent a mechanism for them to survive curcumin 
and sildenafil treatment. We added regorafenib to the curcumin and sildenafil regimen in an 
attempt to circumvent this survival signal by knocking down PDGFR. Regorafenib (as known as 
BAY73-3506 or Stivarga) is a potent multi-kinase inhibitor that was approved for treatment in 
April 27th, 2017.14-16 Studies have shown that regorafenib is involved in the suppression of tumor 
angiogenesis, oncogenesis, and tumor niche formation.62,63,65 More specifically, regorafenib has 
been shown to inhibit tyrosine kinase receptors such as vascular endothelial grow factor 
receptors one, two and three (VEGFR1, VEGFR2, VEGFR3), stromal receptor tyrosine kinases 
such as platelet derived growth factor receptor beta (PDGFRβ), and oncogenic receptor tyrosine 
kinases KIT, RET, RAF, fibroblast growth factor receptor (FGFR) in liver and renal cancer 
cells.62,63,77 Recent studies have shown that regorafenib is effective in treating metastasis in 
CRC.62,63  Regorafenib is also known for increasing reactive oxygen species (ROS) and reactive 
nitrogen species (RNS).110 Regorafenib side effects include; hypomagnesemia, hypopotassemia, 
hypertension, proteinuria, pain, hand-foot skin reaction (HFSR), asthenia/fatigue, diarrhea, 
decreased appetite, infection, dysphonia, elevated bilirubin, fever, mucositis, weight loss, rash, 
high, blood pressure and  nausea.59,64-68 Regorafenib has a very similar chemical structure to that 
of sorafenib the only difference is there is a fluorine substitution to the middle benzene ring.12,14-
16 (Figure 3)  
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Figure 3. Chemical Structures of Sorafenib and Regorafenib108 
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The Focus 
In this study, advanced tumor cells from mice that were previously treated with curcumin 
and sildenafil were shown to over express PDGFR. Over expression of PDGFR indicates there is 
an activating survival signal for these tumor cells. Regorafenib was added to the curcumin and 
sildenafil regimen to circumvent this survival signal by reducing the expression of PDGFR, 
which could potentially lead to more tumor cell death. Potential signal transduction mechanisms 
involved in apoptosis, autophagy and cell survival were investigated. 
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Materials and Methods  
Materials 
All drugs used in this study (Curcumin, Sildenafil Citrate, and Regorafenib) were 
purchased from Selleck Chemicals in Houston, Texas. The cellular culture materials DMEM, 
RPMI, and McCoy’s penicillin-streptomycin, trypsin-EDTA, and PSB were purchased from 
GIBCOBRL (Invitrogen-GIBCOBRL Life Technologies, Grand Island, New York) The Fetal 
Bovine Serum (FBS) was bought from HyClone Laboratories, Inc. (Thermo Scientific Hyclone, 
South Logan, Utah. The 4% paraformaldehyde in PBS can from Alfa Aesar, a subsidiary of 
ThermoFisher Scientific. Both the calcein and the ethidium homodimer-1 used in the 24 hour 
live dead assay came from Life Technologies, another ThermoFisher Scientific subsidiary. Rat 
serum, and DMSO were all purchased from Sigma Chemical (St. Louis, Missouri). For 
transfections, the lipofectamine reagent and Opti-MEM came from Thermo Fisher Scientific. 
The Phospho- and total- primary antibodies used from immunofluorescence were obtained from 
Cell Signaling Technologies (Danvers, Massachusetts) and from Santa Cruz Biotech (Santa 
Cruz, California). Secondary antibodies IRDye 680LT goat anti-rabbit IgG an IRDye 800CW 
goat anti-mouse IgG came from LI-COR Biosciences (Lincoln, Nebraska). The Corning 96 well 
plates came from Sigma Aldrich. Flasks and graduated tubes were purchased from ThermoFisher 
Scientific. Core lab equipment such as the centrifuge and tissue culture hood belong to the 
Massey Cancer Center of Virginia Commonwealth University.   
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Methods 
Cell Culture (In Vitro)   
CT-26 cells were cultured in RPMI Medium 1680 1X supplemented with 2.5 milliliters 
of sterile glucose (250mg/ml-1), 5 milliliters of 1M HEPES, 25 milliliters of 5% fetal bovine 
serum and 5 milliliters of penicillin-streptomycin. HCT-116 cells were cultured in McCoy’s 
medium with 25 milliliters of 5% fetal bovine serum and 5 milliliters of penicillin-streptomycin. 
HT-29 cells were cultured in DMEM supplemented with 25 milliliters of 5% fetal bovine serum 
and 5 milliliters of penicillin-streptomycin. All cells lines were incubated in a humidified 
atmosphere of 5% CO2 at 37˚C.  
 
Cell Counting and Cell Plating 
All the cells used in the study were adherent to the flasks provided. For proper use, cells 
were removed from the adherent surface of the flasks via trypsinization with 0.25 Trypsin-
EDTA. Cells were plated at different densities depending on a specific assay. Cells were plated 
at a density of 3.0 x 103 (per well of a 96-well plate) for immunofluorescence. Cells were plated 
at a density anywhere from 2.5 x 104 to 3.5 x 104 (per 12 well plate) for Trypan Blue exclusion 
assays. Cell lines were then allowed to adhere to the well surface under standard incubation 
conditions for 24-36 hours prior to treatment. 
 
Drug Treatment 
Drug concentrations were chosen based on prior studies performed in the Dent 
laboratory. The concentrations of each drug used in this study were curcumin, sildenafil citrate 
and Regorafenib. Drug solutions were prepared fresh via the combination of the powder drug 
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and solubilized DMSO. Final drug dilution for addition did not exceed 0.1% in final drug 
dilutions. 
 
Transfections of Cells with Plasmids or with siRNA 
For Plasmids: Cells were transfected 24h after plating. Plasmids expressing a specific 
mRNA (or siRNA) or appropriate vector control plasmid DNA was diluted in 50μl serum-free 
and antibiotic-free medium (1 portion for each sample). Concurrently, 2μl Lipofectamine 2000 
(Invitrogen), was diluted into 50μl of serum-free and antibiotic-free medium (1 portion for each 
sample). Diluted DNA was added to the diluted Lipofectamine 2000 for each sample and 
incubated at room temperature for 30 min. This mixture was added to each well / dish of cells 
containing 200μl serum-free and antibiotic-free medium for a total volume of 300 μl, and the 
cells were incubated for 4 h at 37 °C. An equal volume of 2x medium was then added to each 
well. Cells were incubated for 24h, then treated with drugs. 
Transfection for siRNA: Cells from a fresh culture growing in log phase as described 
above, were transfected 24h after plating. Prior to transfection, the medium was aspirated and 
serum-free medium was added to each plate. For transfection, 10 nM of the annealed siRNA, the 
positive sense control doubled stranded siRNA targeting GAPDH or the negative control (a 
“scrambled” sequence with no significant homology to any known gene sequences from mouse, 
rat or human cell lines) were used. Ten nM siRNA (scrambled or experimental) was diluted in 
serum-free media. Four μl Hiperfect (Qiagen) was added to this mixture and the solution was 
mixed by pipetting up and down several times. This solution was incubated at room temp for 10 
min, then added drop-wise to each dish. The medium in each dish was swirled gently to mix, 
then incubated at 37 °C for 2h. Serum-containing medium was added to each plate, and cells 
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were incubated at 37°C for 24h before then treated with drugs (0-24h). Additional immuno-
fluorescence / live-dead analyses were performed at the indicated time points.  
 
Detection of Cell Death by Trypan Blue 
Trypan Blue Exclusion was used to assess cell viability at each experimental time point. 
Floating cells were isolated along with attached cells that were harvested by trypsinization with 
Trypsin/EDTA for approximately 3 to 5 minutes at 37°C. Following isolation, the total cell 
population for each experimental point was assessed for cell viability. 
 
Detection of Protein Expression and Protein Phosphorylation by Immuno-Fluorescence 
using a Hermes WiScan Machine 
Cells (4 x 103 ) were plated into each well of a 96 well plate and allowed to grow over 
night. Depending upon the specific experiment, cells were then either genetically manipulated, or 
treated with drugs. For genetic manipulation, cells were transfected with plasmids or siRNA 
molecules and incubated for an additional 24 hours. Cells were treated with vehicle control or 
with drugs at the indicated final concentrations, alone or in combination. Cells were isolated for 
processing at various times following drug exposure. For immuno-fluorescence studies, after 
centrifugation, cell growth media was removed and cells were fixed in place in 4% 
paraformaldehyde for 10 minutes at room temperature. The cells were then permeabilized using 
ice cold PBS containing 0.5% Triton X-100. After 30 min the cells were washed three times with 
ice cold PBS and pre-blocked with rat serum for 3 hours. Following pre-blocking, cells were 
incubated with a primary antibody for the detection and expression / phosphorylation of a given 
protein (usually at 1:100 dilution from a commercial vendor) overnight at 37˚ C. Following 
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overnight incubation, cells were washed three times with PBS followed by incubation with a 
secondary antibody containing an associated fluorescent red or green chemical tag, for 3 hours. 
Following this incubation, the cells were washed three times in PBS and 100 μl of PBS was 
added to each well for assessment of protein expression. The cells were visualized at either 10x 
or 60x in the Hermes machine. All immunofluorescent images for each individual protein / 
phosphoprotein were recorded using the standardized settings to ensure that signal level for each 
image was directly comparable to signal level in the control and drug treated cells. Similarly, for 
presentation, the enhancement of image brightness/contrast using PhotoShop CS6 was 
simultaneously performed for each individual set of protein/ phospho-protein to permit direct 
comparison of the image intensity between treatments. All immune-fluorescent images were 
initially visualized at 75 dpi using an Odyssey infrared imager (Li-Cor, Lincoln, NE), then 
processed at 9999 dpi using Adobe Photoshop CS6. For presentation, immunoblots were 
digitally assessed using the provided Odyssey imager software. Images have their color removed 
and labeled figures generated in Microsoft PowerPoint. 
 
Live/Dead Assay 
To determine the effectiveness of a given drug treatment on the killing of cancer cells, a 
Live/Dead assay was performed using the Hermes WiScan machine. 10mls/plate FBS was 
prepared with 5μl of calcein (shows live cells) and 5μl of ethidium bromide (shows dying/dead 
cells) as a live dead solution. The live/dead solutions was added to the plate in a volume of 100 
μL/well. The plate was centrifuged at a rate of 200 rpm for 3 minutes and loaded into the Hermes 
WiScan for imaging. Images taken were a representative sample from all wells. The Percentages 
of cell death were determined by ta simple count of the cells within the collected image.   
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Data Analysis 
Comparison of the effects of various treatments was performed using one-way analysis of 
variance and two tailed Student’s t-test. Differences with a p-value of < 0.05 were considered 
statistically significant. Experiments shown are the means of multiple experiments (± SEM). 
 
Cell Lines: 
The cell lines used in this study as well as their major attributes are found in the table below.  
 
Cell Lines Major Attributes 
HT-29 Mutant p53, CD95, Wild Type K-Ras, Mutant 
B-Raf 
HCT-116 Wild Type p53, CD95, Mutant K-Ras  
CT-26 Mutant K-Ras 
 
HCT-116: 
A human colon cancer cell line used in therapeutic research and drug screenings.  
HCT116 cells have a mutation in codon 13 of the K-RAS proto-oncogene, and are suitable 
transfection targets for gene therapy research.70 This human colorectal carcinoma cell line 
initiated from an adult male. The cells are adherent with an epithelial morphology. Following 
implantation into immunocompromised mice, the cells form primary tumors and distant 
metastases. In vitro, HCT116 cells grow with a doubling time of approximately 18 hours. They 
are suitable for in vitro and in vivo experimentation. Immunocompromised mice should be used 
for in life studies, and will form tumors and metastases following implantation of the cells. 
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HT-29:  
A human colorectal adenocarcinoma (a type of cancer that starts in the glands that line 
the inside of one of your organs. Adenocarcinoma can happen in many places, like your colon, 
breasts, esophagus, lungs, pancreas, or prostate) cell line with epithelial morphology.71 HT-29 
cells overproduce the p53 tumor antigen, but have a mutation in the p53 gene at position 273, 
resulting in a histidine replacing an arginine.71 The cells proliferate rapidly in media containing 
suramin, with corresponding high expression of the c-myc oncogene. However, c-myc is 
deregulated, but may have a relation with the growth factor requirements of HT-29 cells. 71 
These cells are sensitive to the chemotherapeutic drugs 5-fluorouracil and oxaliplatin, 
which are standard treatment options for colorectal cancer. In addition to being a xenograft 
tumor model for colorectal cancer, the HT-29 cell line is also used as an in-vitro model to study 
absorption, transport, and secretion by intestinal cells.72-74 Under standard culture conditions, 
these cells grow as a nonpolarized, undifferentiated multilayer. Altering culture conditions or 
treating the cells with various inducers, however, results in a differentiated and polarized 
morphology, characterized by the redistribution of membrane antigens and development of an 
apical brush-border membrane. This cell line was established in 1964 from the primary tumor of 
a 44-year-old Caucasian female with colorectal adenocarcinoma. 71-74 
 
CT-26: 
Murine CT26 (Colon Tumor #26) cells were developed in 1975 by exposing BALB/c 
mice to N-nitroso-N-methylurethane (NMU), resulting in a rapid-growing grade IV carcinoma 
that is easily implanted and readily metastasizes. K-ras, is mutated in CT26. Used in over 500 
published studies, the CT26 colon carcinoma is one of the most commonly used cell lines in drug 
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development. Numerous cytotoxic agents as well as therapeutics targeting specific signaling 
pathways have been studied with these cells. Moreover, as the CT26 model in BALB/c mice 
provides a syngeneic in vivo test system, it is frequently used for developing and testing 
immunotherapeutic concepts. In sharp contrast to its frequent use in drug development, there 
have been no comprehensive studies of the genome and transcriptome of CT26. 75-79 Cdkn2a is 
homozygously deleted. Proliferation and stem-cell markers, including Top2a, Birc5 (Survivin), 
Cldn6 and Mki67, are highly expressed while differentiation and top-crypt markers Muc2, 
Ms4a8a (MS4A8B) and Epcam are not. Myc, Trp53 (tp53), Mdm2, Hif1a, and N-ras are highly 
expressed while EGFR and FLT1 are not. MHC class I but not MHC class II is expressed.80 
 
 
 
Antibodies and SiRNAs  
Antibodies to BAX, BAK, BCL-XL, CHOP, c-FLIP, FADD, Cathepisin B, mTOR, 
phospho-mTOR S2448 and S2481, AIF, NOXA, PUMA, ATG5, phospho-ATG13 S318, Beclin-
1, AKT, phospho-AKT T308, eiF2α, phospho-eiF2α S51, ATM, phospho-ATM S1981, AMPKα, 
phospho-AMPK T172, phospho-ULK1 S757, S317, STAT3, p70 S6K, phospho-ERK1/2, 
GRP78, HSP70 and HSP90, phospho-γH2AX, were purchased from Cell Signaling Technology, 
(Danvers, MA). PERK, CD95 and caspase 9 antibodies, were purchased from Santa Cruz 
Biotechnology, (Dallas, TX). 
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Results: 
 
 
Regorafenib interacts with sildenafil and with curcumin to induce apoptosis in GI tumor 
cells. 
 
Previously, tests on HCT-116 and HT-29 cells were only performed with sildenafil (also 
known as Viagra) and curcumin. The results show that there was significant cell death on these 
colorectal cancer cells. However, cells isolated from in vivo treated [curcumin + sildenafil] 
tumors were resistant to in vitro [curcumin + sildenafil] exposure. The surviving cells had an 
upregulation of PDGFRβ. However, we hypothesized that the late stage colorectal cancer 
therapeutic and PDGFR inhibitor regorafenib would restore the curcumin and sildenafil toxicity 
to a level found in naïve cells. The use of regorafenib in the presence of curcumin and sildenafil 
may represent an effective second line therapy for colorectal cancer patients. Regorafenib (as 
known as BAY73-4506 or Stivarga) is a potent multi-kinase inhibitor that is involved in the 
suppression of tumor angiogenesis, oncogenesis, and tumor niche formation.62,64,65 The lab 
decided to use the [curcumin + sildenafil + regorafenib] drug combination to overcome the 
proliferation signaling provided by the upregulation of PDGFRβ. 6, 12, and 24 hour treatments 
to ascertain the lethality of the drug combination was measured via trypan blue exclusion assay. 
There was a significant increase in cell death in the CT-26, HCT-116, and HT-29 cell lines due 
to drug combination exposure. (Figures 4-6)   
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Trypan Blue Exclusion Assay 
 
  
 
 
 
 
Figure 4. Regorafenib interacts with sildenafil and with curcumin to induce apoptosis in 
CT-26 cell line.  
 
CT-26 cell lines were plated into 12 well plates at a density of 5 x 103/ml and allowed to adhere 
to the plate surface for 12 hours. Cells were then treated a vehicle DMSO, [curcumin (2μM) + 
sildenafil (2μM)], [regorafenib] (2μM) and [curcumin (2μM) + sildenafil (2μM) + regorafenib 
(2μM)] for a 6, 12 and 24 hour period on the 12 well plates. Cell death was determined by the 
trypan blue exclusion assay. The graph depicts a quantification of the percentage of cell death. 
(n=3+/-SEM) # = p <0.05 greater killing compared to the vehicle *= p < 0.05 greater killing 
compared to the [curcumin + sildenafil] treatment.  
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Figure 5. Regorafenib interacts with sildenafil and with curcumin to induce apoptosis in 
HCT-116 cell line.  
 
HCT-116 cell lines were plated into 12 well plates at a density of 5 x 103/ml and allowed to 
adhere to the plate surface for 12 hours. Cells were then treated a vehicle DMSO, [curcumin 
(2μM) + sildenafil (2μM)], [regorafenib] (2μM) and [curcumin (2μM) + sildenafil (2μM) + 
regorafenib (2μM)] for a 6, 12 and 24 hour period on the 12 well plates. Cell death was 
determined by the trypan blue exclusion assay. The graph depicts a quantification of the 
percentage of cell death. (n=3+/-SEM) # = p <0.05 greater killing compared to the vehicle *= p < 
0.05 greater killing compared to the [curcumin + sildenafil] treatment.  
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Figure 6. Regorafenib interacts with sildenafil and with curcumin to induce apoptosis in 
HT-29 cell line.  
 
HT-29 cell lines were plated into 12 well plates at a density of 5 x 103/ml and allowed to adhere 
to the plate surface for 12 hours. Cells were then treated a vehicle DMSO, [curcumin (2μM) + 
sildenafil (2μM)], [regorafenib] (2μM) and [curcumin (2μM) + sildenafil (2μM) + regorafenib 
(2μM)] for a 6, 12 and 24 hour period on the 12 well plates. Cell death was determined by the 
trypan blue exclusion assay. The graph depicts a quantification of the percentage of cell death. 
(n=3+/-SEM)  # = p <0.05 greater killing compared to the vehicle *= p < 0.05 greater killing 
compared to the [curcumin + sildenafil] treatment.  
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Drug combination activates DNA-damage-ATM-AMPK pathway signal transduction 
pathway and inactivates signal transduction pathways that lead to cell proliferation and 
survival in colorectal cancer cells.   
 
Initially, it was determined that the [2μM curcumin + 2μM sildenafil + 2μM regorafenib] 
drug combination causes cell death over time. Logically the next step of inquiry would be to 
observe the activity of signal transduction pathways. Previous studies in the Dent lab have 
focused on the PI3K and MAPK pathways and their roles in autophagy and apoptosis. Frequent 
activation of these pathways occurs when intracellular proteins are phosphorylated by active 
kinases at serine, tyrosine and/or threonine sites. The goal was to investigate the level of 
autophagy/apoptosis by looking at the activity of intracellular proteins in the colorectal tumor 
cells. Treatment of colorectal tumors with [2μM curcumin + 2μM sildenafil + 2μM regorafenib] 
increased the phosphorylation of ATM, AMPK, ULK1 at serine reside 317, ATG-13 at serine 
318, eIF2α, Beclin1 and ATG 5. Concurrently, there was a decrease in phosphorylation with 
proteins normally involved in cell proliferation and cell survival. Proteins such as ULK1 at 
serine reside 757, mToR at serine reside 2448, mToR at serine residue 2481, Bcl-XL and MCL1 
all had reduced expression. (Figures 7-12)   
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Figure 7. Drug combination treatment activates cascade that leads to cell death and 
deactivates cascade that lead to cell proliferation and survival in CT-26 cancer cells.   
 
CT-26 cell lines was plated into a 96 well plate at a density of 5 x 103 cells/ml and allowed to 
adhere to the well surface for 12 hours. Cells were then treated with a vehicle (DMSO), 
[curcumin (2μM) + sildenafil (2μM)], [regorafenib] (2μM) and [curcumin (2μM) + sildenafil 
(2μM) + regorafenib (2μM)] for a 6 hour period on 96 well plates. After treatment, the cells were 
fixed and probed with antibodies to determine the expression and/or phosphorylation of the 
indicated proteins. The images were acquired via a Hermes WiScan machine. The graph depicts 
a quantification of the imaging based off of fluorescent intensity. (n=3+/-SEM) *= (p < 0.05 less 
fluorescence than the vehicle) # = (p < 0.05 less fluorescence compared to the [curcumin + 
sildenafil] treatment) **= (p < 0.05 more fluorescence than the vehicle) ## = (p < 0.05 more 
fluorescence compared to the [curcumin + sildenafil] treatment)  
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Figure 8. Drug combination treatment activates cascade that leads to cell death and 
deactivates cascade that lead to cell proliferation and survival in CT-26 cancer cells.   
 
CT-26 cell lines was plated into a 96 well plate at a density of 5 x 103 cells/ml and allowed to 
adhere to the well surface for 12 hours. Cells were then treated with a vehicle (DMSO), 
[curcumin (2μM) + sildenafil (2μM)], [regorafenib] (2μM) and [curcumin (2μM) + sildenafil 
(2μM) + regorafenib (2μM)] for a 6 hour period on 96 well plates. After treatment, the cells were 
fixed and probed with antibodies to determine the expression and/or phosphorylation of the 
indicated proteins. The images were acquired via a Hermes WiScan machine. The graph depicts 
a quantification of the imaging based off of fluorescent intensity. (n=3+/-SEM) *= (p < 0.05 less 
fluorescence than the vehicle) # = (p < 0.05 less fluorescence compared to the [curcumin + 
sildenafil] treatment) **= (p < 0.05 more fluorescence than the vehicle) ## = (p < 0.05 more 
fluorescence compared to the [curcumin + sildenafil] treatment)  
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Figure 9. Drug combination treatment activates cascade that leads to cell death and 
deactivates cascade that lead to cell proliferation and survival in HCT-116 cancer cells.   
 
HCT-116 cell lines was plated into a 96 well plate at a density of 5 x 103 cells/ml and allowed to 
adhere to the well surface for 12 hours. Cells were then treated with a vehicle (DMSO), 
[curcumin (2μM) + sildenafil (2μM)], [regorafenib] (2μM) and [curcumin (2μM) + sildenafil 
(2μM) + regorafenib (2μM)] for a 6 hour period on 96 well plates. After treatment, the cells were 
fixed and probed with antibodies to determine the expression and/or phosphorylation of the 
indicated proteins. The images were acquired via a Hermes WiScan machine. The graph depicts 
a quantification of the imaging based off of fluorescent intensity. (n=3+/-SEM) *= (p < 0.05 less 
fluorescence than the vehicle) # = (p < 0.05 less fluorescence compared to the [curcumin + 
sildenafil] treatment) **= (p < 0.05 more fluorescence than the vehicle) ## = (p < 0.05 more 
fluorescence compared to the [curcumin + sildenafil] treatment 
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Figure 10. Drug combination treatment activates cascade that leads to cell death and 
deactivates cascade that lead to cell proliferation and survival in HCT-116 cancer cells.   
 
HCT-116 cell lines was plated into a 96 well plate at a density of 5 x 103 cells/ml and allowed to 
adhere to the well surface for 12 hours. Cells were then treated with a vehicle (DMSO), 
[curcumin (2μM) + sildenafil (2μM)], [regorafenib] (2μM) and [curcumin (2μM) + sildenafil 
(2μM) + regorafenib (2μM)] for a 6 hour period on 96 well plates. After treatment, the cells were 
fixed and probed with antibodies to determine the expression and/or phosphorylation of the 
indicated proteins. The images were acquired via a Hermes WiScan machine. The graph depicts 
a quantification of the imaging based off of fluorescent intensity. (n=3+/-SEM) *= (p < 0.05 less 
fluorescence than the vehicle) # = (p < 0.05 less fluorescence compared to the [curcumin + 
sildenafil] treatment) **= (p < 0.05 more fluorescence than the vehicle) ## = (p < 0.05 more 
fluorescence compared to the [curcumin + sildenafil] treatment)  
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Figure 11. Drug combination treatment activates cascade that leads to cell death and 
deactivates cascade that lead to cell proliferation and survival in HT-29 cancer cells.   
 
HT-29 cell lines was plated into a 96 well plate at a density of 5 x 103 cells/ml and allowed to 
adhere to the well surface for 12 hours. Cells were then treated with a vehicle (DMSO), 
[curcumin (2μM) + sildenafil (2μM)], [regorafenib] (2μM) and [curcumin (2μM) + sildenafil 
(2μM) + regorafenib (2μM)] for a 6 hour period on 96 well plates. After treatment, the cells were 
fixed and probed with antibodies to determine the expression and/or phosphorylation of the 
indicated proteins. The images were acquired via a Hermes WiScan machine. The graph depicts 
a quantification of the imaging based off of fluorescent intensity. (n=3+/-SEM) *= (p < 0.05 less 
fluorescence than the vehicle) # = (p < 0.05 less fluorescence compared to the [curcumin + 
sildenafil] treatment) **= (p < 0.05 more fluorescence than the vehicle) ## = (p < 0.05 more 
fluorescence compared to the [curcumin + sildenafil] treatment)  
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Figure 12. Drug combination treatment activates cascade that leads to cell death and 
deactivates cascade that lead to cell proliferation and survival in HT-29 cancer cells.   
 
HT-29 cell lines was plated into a 96 well plate at a density of 5 x 103 cells/ml and allowed to 
adhere to the well surface for 12 hours. Cells were then treated with a vehicle (DMSO), 
[curcumin (2μM) + sildenafil (2μM)], [regorafenib] (2μM) and [curcumin (2μM) + sildenafil 
(2μM) + regorafenib (2μM)] for a 6 hour period on 96 well plates. After treatment, the cells were 
fixed and probed with antibodies to determine the expression and/or phosphorylation of the 
indicated proteins. The images were acquired via a Hermes WiScan machine. The graph depicts 
a quantification of the imaging based off of fluorescent intensity. (n=3+/-SEM) *= (p < 0.05 less 
fluorescence than the vehicle) # = (p < 0.05 less fluorescence compared to the [curcumin + 
sildenafil] treatment) **= (p < 0.05 more fluorescence than the vehicle) ## = (p < 0.05 more 
fluorescence compared to the [curcumin + sildenafil] treatment) 
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Drug treatment induces downregulation of ER stress chaperone proteins and upregulates 
production of apoptotic proteins in CT-26, HCT-116 and HT-29 cells.   
 
In previous studies done in this lab, we have described how curcumin and sildenafil 
induces reactive oxygen species (ROS) to facilitate ER stress on colorectal cancer cells. The next 
step was to test if the [2μM curcumin + 2μM sildenafil + 2μM regorafenib] drug combination 
had any effects on heavily studied ER, autophagic and chaperone proteins. There is an increased 
level of expression on eukaryotic initiation factor 2α (eIF2α). When the [2μM curcumin + 2μM 
sildenafil + 2μM regorafenib] drug combination was used on the CT-26, HCT-116 and HT-29 
there was a significant upregulation of ATG5 and Beclin1. The drug combination, however, 
decreased levels of expression on chaperone proteins heat shock protein 70 and heat shock 
protein 90 (HSP70 and HSP90) and binding immunoglobulin protein (GRP78 as known as BIP). 
These cyto-protective proteins aid in the folding and assembly of proteins inside and outside of 
the ER.85-91 The activity of these proteins attach to other misfolded proteins and works to correct 
the deficient structures before their accumulation triggers apoptosis.85-91 In cancer, there is an 
influx misfolded proteins due to mutations but HSP 70, HSP 90 and GRP 78 are all upregulated 
which decreases misfolded proteins and ultimately decreases the likelihood of apoptosis.85-91  
Reducing the expression of HSP 70, HSP 90 and GRP78 will mean that drug-induced cell killing 
will significantly increase. The hypothesis is synonymous with the results (Figures 13-15)  
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Figure 13. Drug treatment induces downregulation of ER stress chaperone proteins and 
upregulates production of apoptotic proteins in CT-26  
 
CT-26 cell lines were plated into a 96 well plate at a density of 5 x 103 cells/ml and allowed to 
adhere to the well surface for 12 hours. Cells were then treated with a vehicle (DMSO 2μM), 
[curcumin (2μM) + sildenafil (2μM)], [regorafenib] (2μM) and [curcumin (2μM) + sildenafil 
(2μM) + regorafenib (2μM)] drug combination for a 6 hour period on 96 well plates. After 
treatment, the cells were fixed and probed with immune-marker antibodies to determine the 
expression of respective proteins. The images were acquired via a Hermes WiScan machine. The 
graph depicts a quantification of the imaging based off of fluorescent intensity. (n=3+/-SEM) *= 
(p < 0.05 less fluorescence than the vehicle) # = (p < 0.05 less fluorescence compared to the 
[curcumin + sildenafil] treatment) **= (p < 0.05 more fluorescence than the vehicle) ## = p < 
0.05 more fluorescence compared to the [curcumin + sildenafil] treatment. 
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Figure 14. Drug combination treatment induces downregulation of immune receptors, 
enzymes and DNA protective proteins in HCT-116 cells.   
 
HCT-116 cell lines were plated into a 96 well plate at a density of 5 x 103 cells/ml and allowed to 
adhere to the well surface for 12 hours. Cells were then treated with a vehicle (DMSO 2μM), 
[curcumin (2μM) + sildenafil (2μM)], [regorafenib] (2μM) and [curcumin (2μM) + sildenafil 
(2μM) + regorafenib (2μM)] drug combination for a 6 hour period on 96 well plates. After 
treatment, the cells were fixed and probed with immune-marker antibodies to determine the 
expression of respective proteins. The images were acquired via a Hermes WiScan machine. The 
graph depicts a quantification of the imaging based off of fluorescent intensity. (n=3+/-SEM) *= 
(p < 0.05 less fluorescence than the vehicle) # = (p < 0.05 less fluorescence compared to the 
[curcumin + sildenafil] treatment) **= (p < 0.05 more fluorescence than the vehicle) ## = (p < 
0.05 more fluorescence compared to the [curcumin + sildenafil] treatment. 
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Figure 15. Drug combination treatment induces downregulation of immune receptors, 
enzymes and DNA protective proteins in HT-29 cells.   
 
HT-29 cell lines were plated into a 96 well plate at a density of 5 x 103 cells/ml and allowed to 
adhere to the well surface for 12 hours. Cells were then treated with a vehicle (DMSO 2μM), 
[curcumin (2μM) + sildenafil (2μM)], [regorafenib] (2μM) and [curcumin (2μM) + sildenafil 
(2μM) + regorafenib (2μM)] drug combination for a 6 hour period on 96 well plates. After 
treatment, the cells were fixed and probed with immune-marker antibodies to determine the 
expression of respective proteins. The images were acquired via a Hermes WiScan machine. The 
graph depicts a quantification of the imaging based off of fluorescent intensity. (n=3+/-SEM) *= 
(p < 0.05 less fluorescence than the vehicle) # = (p < 0.05 less fluorescence compared to the 
[curcumin + sildenafil] treatment) **= (p < 0.05 more fluorescence than the vehicle) ## = (p < 
0.05 more fluorescence compared to the [curcumin + sildenafil] treatment) 
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Modulation of autophagy and intracellular proteins can suppress [2μM curcumin + 2μM 
sildenafil + 2μM regorafenib] lethality.  
 
Small interfering RNAs (siRNAs) were used to knock down specific proteins. Initial 
studies have indicated that knockdowns of certain key proteins linked to autophagy and 
apoptosis suppress [curcumin + sildenafil] drug lethality. The same step was taking in this study 
with the [2μM curcumin + 2μM sildenafil + 2μM regorafenib] drug combination. The following 
siRNAs were used to evaluate the effectiveness of the drug combination on the HCT-116 and 
HT-29 cell lines: ATG5, Beclin-1, Bax, Bak, Noxa, Puma, ATM, AMPK, ULK1, CD95, FADD, 
eIF2α, Perk, AIF and Cath B. Beclin and ATG5 siRNAs were used because both are essential for 
autophagy. Expression of all proteins that were previously mentioned were suppressed as a result 
of the utilization of siRNAs across both HCT-116 and HT-29 cell lines. With a cytomegalovirus 
(CMV) used as the control, there is a significant reduction in cell death when proteins FLIP, 
BCL-XL, DN caspase9, GRP78, HSP70 were upregulated across both the HT-29 and HCT-116 
cell lines. (Figures 13-20) 
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Transfections (12 Hour Treatment) 
 
 
 
 
 
Figure 16. Knockdown of key autophagy/apoptosis proteins suppressed [2μM curcumin + 
2μM sildenafil + 2μM regorafenib] lethality.  
 
HCT-116 cell lines were plated into 12 well plates at a density of 5 x 103 cells/ml and allowed to 
adhere to the well surface for 12 hours. After that, the HCT-116 cell lines were transfected in 12 
well plates using Opti-MUM and Lipofectamine 2000. The respective small interfering RNAs 
(siRNAs) were deposited into these well and were left to enter the cells for a span not lasting 
more than 30 hours. Cells were then treated with a vehicle (DMSO), [curcumin (2μM) + 
sildenafil (2μM)], [regorafenib] (2μM) and [curcumin (2μM) + sildenafil (2μM) + regorafenib 
(2μM)] for a 12 hour period. The number of dead cells were counted via a trypan blue exclusion 
assay (n=3+/-SEM) * = p < 0.05 less killing compared to the values in scrambled siRNA 
(siSCR) # = p < 0.05 more killing than compared to the [curcumin + sildenafil] knockdown 
treatments. 
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Figure 17. Knockdown of key autophagy/apoptosis proteins suppressed [2μM curcumin + 
2μM sildenafil + 2μM regorafenib] lethality.  
 
HT-29 cell lines were plated into 12 well plates at a density of 5 x 103 cells/ml and allowed to 
adhere to the well surface for 12 hours. After that, the HT-29 cell lines were transfected in 12 
well plates using Opti-MUM and Lipofectamine 2000. The respective small interfering RNAs 
(siRNAs) were deposited into these well and were left to enter the cells for a span not lasting 
more than 30 hours. Cells were then treated with a vehicle (DMSO), [curcumin (2μM) + 
sildenafil (2μM)], [regorafenib] (2μM) and [curcumin (2μM) + sildenafil (2μM) + regorafenib 
(2μM)] for a 12 hour period. The number of dead cells were counted via a trypan blue exclusion 
assay (n=3+/-SEM) * = p < 0.05 less killing compared to the values in scrambled siRNA 
combination treatment (siSCR) # = p < 0.05 more killing than compared to the [curcumin + 
sildenafil] knockdown treatments 
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Figure 18. Knockdown of key autophagy/apoptosis proteins suppressed [2μM curcumin + 
2μM sildenafil + 2μM regorafenib] lethality.  
 
HCT-116 cell lines were plated into 12 well plates at a density of 5 x 103 cells/ml and allowed to 
adhere to the well surface for 12 hours. After that, the HCT-116 cell lines were transfected in 12 
well plates using Opti-MUM and Lipofectamine 2000. The respective small interfering RNAs 
(siRNAs) were deposited into these well and were left to enter the cells for a span not lasting 
more than 30 hours. Cells were then treated with a vehicle (DMSO), [curcumin (2μM) + 
sildenafil (2μM)], [regorafenib] (2μM) and [curcumin (2μM) + sildenafil (2μM) + regorafenib 
(2μM)] for a 12 hour period. The number of dead cells were counted via a trypan blue exclusion 
assay (n=3+/-SEM) * = p < 0.05 less killing than compared to the scrambled siRNA combination 
treatment (siSCR) # = p < 0.05 more killing than compared to the [curcumin + sildenafil] 
knockdown treatments 
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Figure 19. Knockdown of key autophagy/apoptosis proteins suppressed [2μM curcumin + 
2μM sildenafil + 2μM regorafenib] lethality.  
 
HT-29 cell lines were plated into 12 well plates at a density of 5 x 103 cells/ml and allowed to 
adhere to the well surface for 12 hours. After that, the HT-29 cell lines were transfected in 12 
well plates using Opti-MUM and Lipofectamine 2000. The respective small interfering RNAs 
(siRNAs) were deposited into these well and were left to enter the cells for a span not lasting 
more than 30 hours. Cells were then treated with a vehicle (DMSO), [curcumin (2μM) + 
sildenafil (2μM)], [regorafenib] (2μM) and [curcumin (2μM) + sildenafil (2μM) + regorafenib 
(2μM)] for a 12 hour period. The number of dead cells were counted via a trypan blue exclusion 
assay (n=3+/-SEM) * = p < 0.05 less killing compared to the values in scrambled siRNA 
combination treatment (siSCR) # = p < 0.05 more killing compared to the [curcumin + sildenafil] 
treatments. 
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Figure 20. Knockdown of key autophagy/apoptosis proteins suppressed [2μM curcumin + 
2μM sildenafil + 2μM regorafenib] lethality.  
 
HCT-116 cell lines were plated into 12 well plates at a density of 5 x 103 cells/ml and allowed to 
adhere to the well surface for 12 hours. After that, the HCT-116 cell lines were transfected in 12 
well plates using Opti-MUM and Lipofectamine 2000. The respective small interfering RNAs 
(siRNAs) were deposited into these well and were left to enter the cells for a span not lasting 
more than 30 hours. Cells were then treated with a vehicle (DMSO), [curcumin (2μM) + 
sildenafil (2μM)], [regorafenib] (2μM) and [curcumin (2μM) + sildenafil (2μM) + regorafenib 
(2μM)] for a 12 hour period. The number of dead cells were counted via a trypan blue exclusion 
assay (n=3+/-SEM) * = p < 0.05 less killing compared to the scrambled siRNA (siSCR) # = p < 
0.05 more killing compared to the [curcumin + sildenafil] treatments. 
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Figure 21. Knockdown of key autophagy/apoptosis proteins suppressed [2μM curcumin + 
2μM sildenafil + 2μM regorafenib] lethality.  
 
HT-29 cell lines were plated into 12 well plates at a density of 5 x 103 cells/ml and allowed to 
adhere to the well surface for 12 hours. After that, the HT-29 cell lines were transfected in 12 
well plates using Opti-MUM and Lipofectamine 2000. The respective small interfering RNAs 
(siRNAs) were deposited into these well and were left to enter the cells for a span not lasting 
more than 30 hours. Cells were then treated with a vehicle (DMSO), [curcumin (2μM) + 
sildenafil (2μM)], [regorafenib] (2μM) and [curcumin (2μM) + sildenafil (2μM) + regorafenib 
(2μM)] for a 12 hour period. The number of dead cells were counted via a trypan blue exclusion 
assay (n=3+/-SEM) * = p < 0.05 less killing compared to the scrambled siRNA (siSCR) # = p < 
0.05 more killing compared to the [curcumin + sildenafil] treatments.  
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Figure 22. Upregulation of pro-survival proteins suppressed [2μM curcumin + 2μM 
sildenafil + 2μM regorafenib] lethality.  
 
HCT-116 cell lines were plated into a 12 well plates at a density of 5 x 103 cells/ml and allowed 
to adhere to the well surface for 12 hours. After that, the HCT-116 cell lines were infected with 
CMV plasmids in 12 well plates using Opti-MUM. The respective plasmids were deposited into 
these wells and were left to enter the cells for a span not lasting more than 30 hours. Cells were 
then treated with a vehicle (DMSO), [curcumin (2μM) + sildenafil (2μM)], [regorafenib] (2μM) 
and [curcumin (2μM) + sildenafil (2μM) + regorafenib (2μM)] for a 12 hour period. The number 
of dead cells were counted via a trypan blue exclusion assay (n=3+/-SEM) *= p < 0.05 less 
killing compared to cytomegalovirus control (CMV) # = p < 0.05 more killing compared to the 
[curcumin + sildenafil] treatments.  
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Figure 23. Upregulation of pro-survival proteins suppressed [2μM curcumin + 2μM 
sildenafil + 2μM regorafenib] lethality.  
 
HT-29 cell lines were plated into a 12 well plates at a density of 5 x 103 cells/ml and allowed to 
adhere to the well surface for 12 hours. After that, the HT-29 cell lines were infected with CMV 
plasmids in 12 well plates using Opti-MUM. The respective plasmids were deposited into these 
wells and were left to enter the cells for a span not lasting more than 30 hours. Cells were then 
treated with a vehicle (DMSO), [curcumin (2μM) + sildenafil (2μM)], [regorafenib] (2μM) and 
[curcumin (2μM) + sildenafil (2μM) + regorafenib (2μM)] for a 12 hour period. The number of 
dead cells were counted via a trypan blue exclusion assay. (n=3+/-SEM) * = p < 0.05 less killing 
than corresponding values in cytomegalovirus (CMV) 
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[2μM curcumin + 2μM sildenafil + 2μM regorafenib] drug combination induces an overall 
inhibition of HDACs in CT-26, HCT-116, and HT-29 cell line 
 
In the CT-26, HCT-116 and HT-29 cell line there was an overall decrease in expression 
of HDACs proteins when the [2μM curcumin + 2μM sildenafil + 2μM regorafenib] drug 
combination was used. The Dent lab has shown that autophagy can facilitate the rapid 
degradation of a wide variety of signal transduction regulatory proteins. Moreover, it was 
demonstrated that autophagy can contribute to the degradation of HDAC proteins. Treatment of 
CT-26 cells with the [2μM curcumin + 2μM sildenafil + 2μM regorafenib] drug combination had 
decreased fluorescent intensity for HDACs 1-7, 9-11 compared to the vehicle. The [2μM 
curcumin + 2μM sildenafil] drug combination had decreased fluorescent intensity for HDACs 1-
11 compared to the vehicle. With regorafenib, there were decreases in fluorescent intensity for 
HDACs 1-3,6, 8-11 compared to the vehicle however the decrease wasn’t as significant as the 
curcumin/sildenafil and [2μM curcumin + 2μM sildenafil + 2μM regorafenib] drug 
combinations. HDAC expression was decrease across the HCT-116 and HT-29 cell lines as well 
except HDAC 10 in the HCT-116 (Figure 21-23).   
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Figure 24. Histone Deacylases (HDACs) 1-11 are repressed in CT-26 tissues. 
 
CT-26 cell lines was plated into a 96 well plate at a density of 5 x 103 cells/ml and allowed to 
adhere to the well surface for 12 hours. Cells were then treated with a vehicle (DMSO), 
[curcumin (2μM) + sildenafil (2μM)], [regorafenib] (2μM) and [curcumin (2μM) + sildenafil 
(2μM) + regorafenib (2μM)] for a 12 hour period on 96 well plates. After treatment, the cells 
were fixed and probed with HDAC antibodies to determine the expression of HDACs. The 
images were acquired via a Hermes WiScan machine. The graph depicts a quantification of the 
imaging based off of fluorescent intensity. (n=3 +/-SEM) *= p < 0.05 less HDAC expression 
compared to the vehicle. # = p < 0.05 less HDAC expression compared to the [curcumin + 
sildenafil] treatment. ## = p< 0.05 more HDAC expression compared the vehicle.   
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Figure 25. Histone Deacylases (HDACs) 1-11 are repressed in HCT-116 tissues. 
 
HCT-116 cell lines was plated into a 96 well plate at a density of 5 x 103 cells/ml and allowed to 
adhere to the well surface for 12 hours. Cells were then treated with a vehicle (DMSO), 
[curcumin (2μM) + sildenafil (2μM)], [regorafenib] (2μM) and [curcumin (2μM) + sildenafil 
(2μM) + regorafenib (2μM)] for a 12 hour period on 96 well plates. After treatment, the cells 
were fixed and probed with HDAC antibodies to determine the expression of HDACs. The 
images were acquired via a Hermes WiScan machine. The graph depicts a quantification of the 
imaging based off of fluorescent intensity. (n=3 +/-SEM) *= p < 0.05 less HDAC expression 
compared to the vehicle. # = p< 0.05 less HDAC expression compared to the [curcumin + 
sildenafil] treatment.  ## = p< 0.05 more HDAC expression compared the vehicle.   
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Figure 26. Histone Deacylases (HDACs) 1-11 are repressed in HT-29 tissues. 
 
HT-29 cell lines was plated into a 96 well plate at a density of 5 x 103 cells/ml and allowed to 
adhere to the well surface for 12 hours. Cells were then treated with a vehicle (DMSO), 
[curcumin (2μM) + sildenafil (2μM)], [regorafenib] (2μM) and [curcumin (2μM) + sildenafil 
(2μM) + regorafenib (2μM)] for a 12 hour period on 96 well plates. After treatment, the cells 
were fixed and probed with HDAC antibodies to determine the expression of HDACs. The 
images were acquired via a Hermes WiScan machine. The graph depicts a quantification of the 
imaging based off of fluorescent intensity. (n=3 +/-SEM) *= p < 0.05 less HDAC expression 
compared to the vehicle. # = p < 0.05 less HDAC expression compared to the [curcumin + 
sildenafil] treatment 
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Drug combination treatment induces downregulation of immune checkpoint proteins and 
enzymes in CT-26 HT-29 and HCT-116 cells.   
 
 
The next step in this study is to determine if there is a correlation between reduced 
HDAC expression and proteins levels that alter immunogenicity of colorectal tumor cells to 
checkpoint inhibitory immunotherapies. The immune checkpoint protein and enzyme levels of 
PDL1, PDL2, MHCA1, ODC and IDO were observed. There is an apparent downregulation of 
Programmed Cell Death Ligand-1 (PDL1), Programmed Cell Death Ligand-2 (PDL2), 
Indoleamine 2,3-dioxygenase 1 (IDO1) Ornithine decarboxylase (ODC) across the CT-26, HCT-
116 and HT-29 cell lines when the [2μM curcumin + 2μM sildenafil + 2μM regorafenib] drug 
combination is used. Major Histocompatibility Complex (MHCA1) had a significant increase in 
expression across all three colorectal tumor cell lines (Figures 24-26).  
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Figure 27. Drug combination treatment induces downregulation of immune checkpoint 
proteins and enzymes in CT-26 cells.   
 
CT-26 cell lines was plated into a 96 well plate at a density of 5 x 103 cells/ml and allowed to 
adhere to the well surface for 12 hours. Cells were then treated with a vehicle (DMSO), 
[curcumin (2μM) + sildenafil (2μM)], [regorafenib] (2μM) and [curcumin (2μM) + sildenafil 
(2μM) + regorafenib (2μM)] for a 6 hour period on 96 well plates. After treatment, the cells were 
fixed and probed with immune-marker antibodies. The images were acquired via a Hermes 
WiScan machine. The graph depicts a quantification of the imaging based off of fluorescent 
intensity. (n=3 +/-SEM) *= p < 0.05 less expression compared to the vehicle. # = p < 0.05 less 
expression compared to the [curcumin + sildenafil] treatment. **= p < 0.05 more expression 
compared to the vehicle. ##= p < 0.05 more expression to the [curcumin + sildenafil] treatment.    
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Figure 28. Drug combination treatment induces downregulation of immune checkpoint 
proteins and enzymes in HCT-116 cells.   
 
HCT-116 cell lines was plated into a 96 well plate at a density of 5 x 103 cells/ml and allowed to 
adhere to the well surface for 12 hours. Cells were then treated with a vehicle (DMSO), 
[curcumin (2μM) + sildenafil (2μM)], [regorafenib] (2μM) and [curcumin (2μM) + sildenafil 
(2μM) + regorafenib (2μM)] for a 6 hour period on 96 well plates. After treatment, the cells were 
fixed and probed with immune-marker antibodies. The images were acquired via a Hermes 
WiScan machine. The graph depicts a quantification of the imaging based off of fluorescent 
intensity. (n=3 +/-SEM) *= p < 0.05 less expression compared to the vehicle. # = p < 0.05 less 
expression compared to the [curcumin + sildenafil] treatment. **= p < 0.05 more expression 
compared to the vehicle. ##= p < 0.05 more expression to the [curcumin + sildenafil] treatment.    
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Figure 29. Drug combination treatment induces downregulation of immune checkpoint 
proteins and enzymes in HT-29 cells.   
 
HT-29 cell lines was plated into a 96 well plate at a density of 5 x 103 cells/ml and allowed to 
adhere to the well surface for 12 hours. Cells were then treated with a vehicle (DMSO), 
[curcumin (2μM) + sildenafil (2μM)], [regorafenib] (2μM) and [curcumin (2μM) + sildenafil 
(2μM) + regorafenib (2μM)] for a 6 hour period on 96 well plates. After treatment, the cells were 
fixed and probed with immune-marker antibodies. The images were acquired via a Hermes 
WiScan machine. The graph depicts a quantification of the imaging based off of fluorescent 
intensity. (n=3 +/-SEM) *= p < 0.05 less expression compared to the vehicle. # = p < 0.05 less 
expression compared to the [curcumin + sildenafil] treatment. **= p < 0.05 more expression 
compared to the vehicle. ##= p < 0.05 more expression to the [curcumin + sildenafil] treatment.    
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Activations of PDGFR, Raf-1, ERBB1, ERBB2, ERBB3, and B-raf were halted with [2μM 
curcumin + 2μM sildenafil + 2μM regorafenib] drug combination in colorectal tumor cells.  
 
Previous attempts to treat colorectal cancer cells in the lab proved to be noteworthy. At 
the time, the [curcumin + sildenafil] drug combination were significantly increasing ROS. This 
in turn increased lethality and caused cell death. However, when cells isolated from in vivo 
treated [curcumin + sildenafil] tumors were resistant to in vitro [curcumin + sildenafil] exposure, 
the lab decided to utilize the efficacy of regorafenib. It is known that regorafenib is shown to be 
effective in treating colorectal cancers, more specifically it can reduce the activity levels of 
PDGFRβ, B-raf, and Raf-1. When using [2μM curcumin + 2μM sildenafil + 2μM regorafenib] 
drug combination, there was a decrease in PDGFRβ, Raf-1, ERBB1, ERBB2, ERBB3, and B-raf 
in the HCT-116 and HT-29 cell lines. However, ERBB3 in HT-29, however showed an increase 
in activity (Figures 30-33)  
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Figure 30. Activations of PDGFR, Raf-1, ERBB1, ERBB2, ERBB3, and B-raf were halted 
with [2μM curcumin + 2μM sildenafil + 2μM regorafenib] drug combination in colorectal 
tumor cells.  
 
HCT-116 cell lines were treated with a vehicle (DMSO 2μM), [curcumin (2μM) + sildenafil 
(2μM)], [regorafenib] (2μM) and [curcumin (2μM) + sildenafil (2μM) + regorafenib (2μM)] drug 
combination for a 4 hour period on 96 well plates. After treatment, the cells were fixed and 
probed with antibodies to determine receptor activity. The images were acquired via a Hermes 
WiScan machine. The graph depict a quantification of the imaging based off of fluorescent 
intensity. (n=3+/- SEM) * = p < 0.05 more receptor expression compared to the vehicle. **= p < 
0.05 less receptor expression compared to the vehicle. # = p < 0.05 more receptor expression 
compared to the [curcumin + sildenafil] treatment.  
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Figure 31. Activations of PDGFR, Raf-1, ERBB1, ERBB2, ERBB3, and B-raf were halted 
with [2μM curcumin + 2μM sildenafil + 2μM regorafenib] drug combination in colorectal 
tumor cells.  
 
HCT-116 cell lines were treated with a vehicle (DMSO 2μM), [curcumin (2μM) + sildenafil 
(2μM)], [regorafenib] (2μM) and [curcumin (2μM) + sildenafil (2μM) + regorafenib (2μM)] drug 
combination for a 4 hour period on 96 well plates. After treatment, the cells were fixed and 
probed with antibodies to determine receptor activity. The images were acquired via a Hermes 
WiScan machine. The graph depict a quantification of the imaging based off of fluorescent 
intensity. (n=3+/- SEM) * = p < 0.05 less receptor expression compared to the vehicle. **= p < 
0.05 more receptor expression compared to the vehicle. # = p < 0.05 less receptor expression 
compared to the [curcumin + sildenafil] treatment. 
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Figure 32. Activations of PDGFR, Raf-1, ERBB1, ERBB2, ERBB3, and B-raf were halted 
with [2μM curcumin + 2μM sildenafil + 2μM regorafenib] drug combination in colorectal 
tumor cells.  
 
HT-29 cell lines were treated with a vehicle (DMSO 2μM), [curcumin (2μM) + sildenafil 
(2μM)], [regorafenib] (2μM) and [curcumin (2μM) + sildenafil (2μM) + regorafenib (2μM)] drug 
combination for a 4 hour period on 96 well plates. After treatment, the cells were fixed and 
probed with antibodies to determine receptor activity. The images were acquired via a Hermes 
WiScan machine. The graph depict a quantification of the imaging based off of fluorescent 
intensity. (n=3+/- SEM) ** = p < 0.05 less receptor expression compared to the vehicle. * = p < 
0.05 more receptor expression compared to the vehicle. # = p < 0.05 less receptor expression 
compared to the [curcumin + sildenafil] treatment. ## = p < 0.05 more receptor expression 
compared to the [curcumin + sildenafil] treatment. 
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Figure 33. Activations of PDGFR, Raf-1, ERBB1, ERBB2, ERBB3, and B-raf were halted 
with [2μM curcumin + 2μM sildenafil + 2μM regorafenib] drug combination in colorectal 
tumor cells.  
 
HT-29 cell lines were treated with a vehicle (DMSO 2μM), [curcumin (2μM) + sildenafil 
(2μM)], [regorafenib] (2μM) and [curcumin (2μM) + sildenafil (2μM) + regorafenib (2μM)] drug 
combination for a 4 hour period on 96 well plates. After treatment, the cells were fixed and 
probed with antibodies to determine receptor activity. The images were acquired via a Hermes 
WiScan machine. The graph depict a quantification of the imaging based off of fluorescent 
intensity. (n=3+/- SEM) ** = p < 0.05 more receptor expression compared to the vehicle. * = p < 
0.05 less receptor expression compared to the vehicle. ## = p < 0.05 less receptor expression 
compared to the [curcumin + sildenafil] treatment. # = p < 0.05 less receptor expression 
compared to the [curcumin + sildenafil] treatment.  
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Immunofluorescence reveals knockdown of essential downstream regulators increases cyto-
protective and anti-apoptotic protein productivity even when [2μM curcumin + 2μM 
sildenafil + 2μM regorafenib] drug combination is used on colorectal tumor cells.  
 
The next step in this study was to utilize siRNAs to detect the activity of cyto-protective 
proteins. Initial studies have indicated that knockdowns for certain key proteins that are linked to 
autophagy and apoptosis will suppress drug lethality. The effort was refocused on three specific 
proteins BCL-XL, MCL1, and mToR due to the fact that they have high activity levels in tumor 
cells. Moreover, ATG13 was looked at as well to see its activity as a result of the knockdowns. 
The siRNAs knockdown PERK, eIF2α, Beclin, CD95, ATM and AMPK. Expression of BCL-XL 
and MCL1 proteins were increased across the HCT-116 and HT-29 cell lines as a result of the 
utilization of siRNAs, even with the use of [2μM curcumin + 2μM sildenafil + 2μM regorafenib] 
drug combination. There was a decrease in the expression of ATG13 and mToR when [2μM 
curcumin + 2μM sildenafil + 2μM regorafenib] drug combination was used. (Figures 34-41) 
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Figure 34. Knockdown of essential downstream regulators increases cyto-protective and 
anti-apoptotic protein productivity even when [2μM curcumin + 2μM sildenafil + 2μM 
regorafenib] drug combination is used on colorectal tumor cells 
 
HCT-116 cell lines were plated into a 96 well plate at a density of 5 x 103 cells/ml and allowed to 
adhere to the well surface for 12 hours. After that, the HCT-116 cell lines were transfected in 12 
well plates using Opti-MUM and Lipofectamine 2000. The respective small interfering RNAs 
(siRNAs) were deposited into these well and were left to enter the cells for a span not lasting 
more than 30 hours. Cells were then treated with a vehicle (DMSO), [curcumin (2μM) + 
sildenafil (2μM)], [regorafenib] (2μM) and [curcumin (2μM) + sildenafil (2μM) + regorafenib 
(2μM)] for a 6 hour period on 96 well plates. After treatment, the cells were fixed and probed 
with antibodies to determine the expression and/or phosphorylation of the indicated proteins. The 
images were acquired via a Hermes WiScan machine. The graph depicts a quantification of the 
imaging based off of fluorescent intensity. (n=3+/-SEM) *= p < 0.05 less fluorescence compared 
to the scrambled vehicle **= p <0.05 more fluorescence compared to the scrambled vehicle # = p 
< 0.05 less fluorescence compared to the [curcumin + sildenafil] treatment.  
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Figure 35. Knockdown of essential downstream regulators increases cyto-protective and 
anti-apoptotic protein productivity even when [2μM curcumin + 2μM sildenafil + 2μM 
regorafenib] drug combination is used on colorectal tumor cells 
 
HCT-116 cell lines were plated into a 96 well plate at a density of 5 x 103 cells/ml and allowed to 
adhere to the well surface for 12 hours. After that, the HCT-116 cell lines were transfected in 12 
well plates using Opti-MUM and Lipofectamine 2000. The respective small interfering RNAs 
(siRNAs) were deposited into these well and were left to enter the cells for a span not lasting 
more than 30 hours. Cells were then treated with a vehicle (DMSO), [curcumin (2μM) + 
sildenafil (2μM)], [regorafenib] (2μM) and [curcumin (2μM) + sildenafil (2μM) + regorafenib 
(2μM)] for a 6 hour period on 96 well plates. After treatment, the cells were fixed and probed 
with antibodies to determine the expression and/or phosphorylation of the indicated proteins. The 
images were acquired via a Hermes WiScan machine. The graph depicts a quantification of the 
imaging based off of fluorescent intensity. (n=3+/-SEM) *= p < 0.05 less fluorescence compared 
to the scrambled vehicle **= p <0.05 more fluorescence compared to the scrambled vehicle # = p 
< 0.05 less fluorescence compared to the [curcumin + sildenafil] treatment. ## = p < 0.05 more 
fluorescence compared to the [curcumin + sildenafil] treatment.  
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Figure 36. Knockdown of essential downstream regulators decreases pro-apoptotic protein 
productivity even when [2μM curcumin + 2μM sildenafil + 2μM regorafenib] drug 
combination is used on colorectal tumor cells 
 
HCT-116 cell lines were plated into a 96 well plate at a density of 5 x 103 cells/ml and allowed to 
adhere to the well surface for 12 hours. After that, the HCT-116 cell lines were transfected in 12 
well plates using Opti-MUM and Lipofectamine 2000. The respective small interfering RNAs 
(siRNAs) were deposited into these well and were left to enter the cells for a span not lasting 
more than 30 hours. Cells were then treated with a vehicle (DMSO), [curcumin (2μM) + 
sildenafil (2μM)], [regorafenib] (2μM) and [curcumin (2μM) + sildenafil (2μM) + regorafenib 
(2μM)] for a 6 hour period on 96 well plates. After treatment, the cells were fixed and probed 
with antibodies to determine the expression and/or phosphorylation of the indicated proteins. The 
images were acquired via a Hermes WiScan machine. The graph depicts a quantification of the 
imaging based off of fluorescent intensity. (n=3+/-SEM) *= p < 0.05 less fluorescence compared 
to the scrambled vehicle # = p < 0.05 less fluorescence compared to the [curcumin + sildenafil] 
treatment.  
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Figure 37. Knockdown of essential downstream regulators affect mToR productivity even 
when [2μM curcumin + 2μM sildenafil + 2μM regorafenib] drug combination is used on 
colorectal tumor cells 
 
HCT-116 cell lines were plated into a 96 well plate at a density of 5 x 103 cells/ml and allowed to 
adhere to the well surface for 12 hours. After that, the HCT-116 cell lines were transfected in 12 
well plates using Opti-MUM and Lipofectamine 2000. The respective small interfering RNAs 
(siRNAs) were deposited into these well and were left to enter the cells for a span not lasting 
more than 30 hours. Cells were then treated with a vehicle (DMSO), [curcumin (2μM) + 
sildenafil (2μM)], [regorafenib] (2μM) and [curcumin (2μM) + sildenafil (2μM) + regorafenib 
(2μM)] for a 6 hour period on 96 well plates. After treatment, the cells were fixed and probed 
with antibodies to determine the expression and/or phosphorylation of the indicated proteins. The 
images were acquired via a Hermes WiScan machine. The graph depicts a quantification of the 
imaging based off of fluorescent intensity. (n=3+/-SEM) *= p < 0.05 less fluorescence compared 
to the scrambled vehicle # = p < 0.05 less fluorescence compared to the [curcumin + sildenafil] 
treatment.  
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Figure 38. Knockdown of essential downstream regulators increases cyto-protective and 
anti-apoptotic protein productivity even when [2μM curcumin + 2μM sildenafil + 2μM 
regorafenib] drug combination is used on colorectal tumor cells 
 
HT-29 cell lines were plated into a 96 well plate at a density of 5 x 103 cells/ml and allowed to 
adhere to the well surface for 12 hours. After that, the HCT-116 cell lines were transfected in 12 
well plates using Opti-MUM and Lipofectamine 2000. The respective small interfering RNAs 
(siRNAs) were deposited into these well and were left to enter the cells for a span not lasting 
more than 30 hours. Cells were then treated with a vehicle (DMSO), [curcumin (2μM) + 
sildenafil (2μM)], [regorafenib] (2μM) and [curcumin (2μM) + sildenafil (2μM) + regorafenib 
(2μM)] for a 6 hour period on 96 well plates. After treatment, the cells were fixed and probed 
with antibodies to determine the expression and/or phosphorylation of the indicated proteins. The 
images were acquired via a Hermes WiScan machine. The graph depicts a quantification of the 
imaging based off of fluorescent intensity. (n=3+/-SEM) *= p < 0.05 less fluorescence compared 
to the scrambled vehicle # = p < 0.05 less fluorescence compared to the [curcumin + sildenafil] 
treatment.  
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Figure 39. Knockdown of essential downstream regulators increases cyto-protective and 
anti-apoptotic protein productivity even when [2μM curcumin + 2μM sildenafil + 2μM 
regorafenib] drug combination is used on colorectal tumor cells 
 
HT-29 cell lines were plated into a 96 well plate at a density of 5 x 103 cells/ml and allowed to 
adhere to the well surface for 12 hours. After that, the HCT-116 cell lines were transfected in 12 
well plates using Opti-MUM and Lipofectamine 2000. The respective small interfering RNAs 
(siRNAs) were deposited into these well and were left to enter the cells for a span not lasting 
more than 30 hours. Cells were then treated with a vehicle (DMSO), [curcumin (2μM) + 
sildenafil (2μM)], [regorafenib] (2μM) and [curcumin (2μM) + sildenafil (2μM) + regorafenib 
(2μM)] for a 6 hour period on 96 well plates. After treatment, the cells were fixed and probed 
with antibodies to determine the expression and/or phosphorylation of the indicated proteins. The 
images were acquired via a Hermes WiScan machine. The graph depicts a quantification of the 
imaging based off of fluorescent intensity. (n=3+/-SEM) *= p < 0.05 less fluorescence compared 
to the scrambled vehicle # = p < 0.05 less fluorescence compared to the [curcumin + sildenafil] 
treatment.  
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Figure 40. Knockdown of essential downstream regulators decreases pro-apoptotic protein 
productivity even when [2μM curcumin + 2μM sildenafil + 2μM regorafenib] drug 
combination is used on colorectal tumor cells 
 
HT-29 cell lines were plated into a 96 well plate at a density of 5 x 103 cells/ml and allowed to 
adhere to the well surface for 12 hours. After that, the HCT-116 cell lines were transfected in 12 
well plates using Opti-MUM and Lipofectamine 2000. The respective small interfering RNAs 
(siRNAs) were deposited into these well and were left to enter the cells for a span not lasting 
more than 30 hours. Cells were then treated with a vehicle (DMSO), [curcumin (2μM) + 
sildenafil (2μM)], [regorafenib] (2μM) and [curcumin (2μM) + sildenafil (2μM) + regorafenib 
(2μM)] for a 6 hour period on 96 well plates. After treatment, the cells were fixed and probed 
with antibodies to determine the expression and/or phosphorylation of the indicated proteins. The 
images were acquired via a Hermes WiScan machine. The graph depicts a quantification of the 
imaging based off of fluorescent intensity. (n=3+/-SEM) *= p < 0.05 less fluorescence compared 
to the scrambled vehicle # = p < 0.05 less fluorescence compared to the [curcumin + sildenafil] 
treatment.  
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Figure 41. Knockdown of essential downstream regulators affect mToR productivity even 
when [2μM curcumin + 2μM sildenafil + 2μM regorafenib] drug combination is used on 
colorectal tumor cells 
 
HT-29 cell lines were plated into a 96 well plate at a density of 5 x 103 cells/ml and allowed to 
adhere to the well surface for 12 hours. After that, the HCT-116 cell lines were transfected in 12 
well plates using Opti-MUM and Lipofectamine 2000. The respective small interfering RNAs 
(siRNAs) were deposited into these well and were left to enter the cells for a span not lasting 
more than 30 hours. Cells were then treated with a vehicle (DMSO), [curcumin (2μM) + 
sildenafil (2μM)], [regorafenib] (2μM) and [curcumin (2μM) + sildenafil (2μM) + regorafenib 
(2μM)] for a 6 hour period on 96 well plates. After treatment, the cells were fixed and probed 
with antibodies to determine the expression and/or phosphorylation of the indicated proteins. The 
images were acquired via a Hermes WiScan machine. The graph depicts a quantification of the 
imaging based off of fluorescent intensity. (n=3+/-SEM) *= p < 0.05 less fluorescence compared 
to the scrambled vehicle # = p < 0.05 less fluorescence compared to the [curcumin + sildenafil] 
treatment.  
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Immunofluorescence reveals knockdown of essential downstream regulators decreases 
eIF2α activity levels when [2μM curcumin + 2μM sildenafil + 2μM regorafenib] drug 
combination is used on colorectal tumor cells.  
 
96 well plates were re-probed with P-eIF2α to view the levels of activity. Across the 
HCT-116 and HT-29 cell line, there is decreased activity in protein synthesis when Perk, eIF2α, 
Beclin, CD95, ATM and AMPK were knockdown. There is a significant downregulation of 
eIF2a across both the HCT-116 and HT-29 cell lines. (Figure 42-43) 
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Figure 42. Knockdown of essential downstream regulators decreases pro-apoptotic protein 
productivity even when [2μM curcumin + 2μM sildenafil + 2μM regorafenib] drug 
combination is used on colorectal tumor cells 
 
HCT-116 cell lines were plated into a 96 well plate at a density of 5 x 103 cells/ml and allowed to 
adhere to the well surface for 12 hours. After that, the HCT-116 cell lines were transfected in 12 
well plates using Opti-MUM and Lipofectamine 2000. The respective small interfering RNAs 
(siRNAs) were deposited into these well and were left to enter the cells for a span not lasting 
more than 30 hours. Cells were then treated with a vehicle (DMSO), [curcumin (2μM) + 
sildenafil (2μM)], [regorafenib] (2μM) and [curcumin (2μM) + sildenafil (2μM) + regorafenib 
(2μM)] for a 6 hour period on 96 well plates. After treatment, the cells were fixed and probed 
with antibodies to determine the expression and/or phosphorylation of the indicated proteins. The 
images were acquired via a Hermes WiScan machine. The graph depicts a quantification of the 
imaging based off of fluorescent intensity. (n=3+/-SEM) *= p < 0.05 less fluorescence compared 
to the scrambled vehicle ## = p < 0.05 more fluorescence compared to the [curcumin + 
sildenafil] treatment.  
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Figure 43. Knockdown of essential downstream regulators decreases pro-apoptotic protein 
productivity even when [2μM curcumin + 2μM sildenafil + 2μM regorafenib] drug 
combination is used on colorectal tumor cells 
 
HT-29 cell lines were plated into a 96 well plate at a density of 5 x 103 cells/ml and allowed to 
adhere to the well surface for 12 hours. After that, the HCT-116 cell lines were transfected in 12 
well plates using Opti-MUM and Lipofectamine 2000. The respective small interfering RNAs 
(siRNAs) were deposited into these well and were left to enter the cells for a span not lasting 
more than 30 hours. Cells were then treated with a vehicle (DMSO), [curcumin (2μM) + 
sildenafil (2μM)], [regorafenib] (2μM) and [curcumin (2μM) + sildenafil (2μM) + regorafenib 
(2μM)] for a 6 hour period on 96 well plates. After treatment, the cells were fixed and probed 
with antibodies to determine the expression and/or phosphorylation of the indicated proteins. The 
images were acquired via a Hermes WiScan machine. The graph depicts a quantification of the 
imaging based off of fluorescent intensity. (n=3+/-SEM) *= p < 0.05 less fluorescence compared 
to the scrambled vehicle ## = p < 0.05 more fluorescence compared to the [curcumin + 
sildenafil] treatment. 
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Animal studies reveal the efficacy of [2μM curcumin + 2μM sildenafil + 2μM regorafenib] 
drug combination over a course of 30 days. 
 
 
Immuno-competent BALB/c mice were ejected with CT-26 colorectal tumor cells and were 
allowed to grow for 7 days. The results show that, compared to the vehicle, drug combination 
significantly reduced tumor size at the end of the study. (Figures 44)  
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Figure 44. Animal Studies reveal the efficacy of [2μM curcumin + 2μM sildenafil + 2μM 
regorafenib] drug combination over the course of a 30 day period 
 
Immuno-competent BALB/c mice (~20 g) were injected with 1x106 CT-26 cells into their rear 
flank. Tumors were permitted to form for 7 days with tumors at the time exhibiting a volume of 
~35 to ~45mm3. Mice were treated by oral gavage once every BID for 30 days with vehicle, 
curcumin (50mg/kg), sildenafil (10mg/kg), regorafenib (10mg/kg) on days 1-5 or in combination 
as indicated. Tumors were callipered and tumor volumes were determined before and following 
drug exposure. (n=18 +/- SEM) * = p < 0.05 less tumor growth compared to vehicle. 
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Discussion 
The aforementioned study was designed to determine whether very low clinically 
achievable concentrations of curcumin and sildenafil could have their anti-cancer properties 
enhanced by the multi-tyrosine kinase inhibitor, regorafenib. The rationale behind this study is 
derived from previous findings in our laboratory that demonstrated that tumors that were 
previously exposed to curcumin and sildenafil, displayed an increase in activated PDGFR which 
was correlated with elevated levels of PDGF in mouse plasma.11 These tumor cells were resistant 
to subsequent re-exposure to curcumin and sildenafil. Thus, increased activation of PDGFR 
signaling represents a key evolutionary survival mechanism of gastrointestinal tumor cells 
exposed to curcumin and sildenafil. The precise mechanisms downstream of PDGFR that 
mediate resistance to curcumin and sildenafil are presently unknown. The hypothesis of this study 
is that a late stage colorectal cancer therapeutic and PDGFR inhibitor regorafenib would restore 
curcumin and sildenafil lethality to a level found in naïve cells. The use of regorafenib in the 
presence of curcumin and sildenafil may represent an effective second line therapy for colorectal 
cancer patients. Regorafenib (as known as BAY73-4506 or Stivarga) is a potent multi-kinase 
inhibitor that is involved in the suppression of tumor angiogenesis, oncogenesis, and tumor niche 
formation.62,64,65 More specifically, Regorafenib has been shown to inhibit tyrosine kinase 
receptors such as vascular endothelial grow factor receptors one, two and three 
(VEGFR1, VEGFR2, VEGFR3), platelet derived growth factor receptor beta (PDGFRβ), Kit, B-
Raf, RET, Raf-1, fibroblast growth factor receptor (FGFR), halt metastasis in liver and colorectal 
cancer cells and increase the levels of ROS and RNS.11,16,60,62, Isoforms and receptors of PDGF 
have important functions in the regulation of growth and survival of certain cell types during 
embryonal development and e.g. tissue repair in the adult. Upregulation of PDGF receptor 
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signaling, by over expression of receptor / ligand or receptor mutational events, may drive tumor 
cell growth.92 Studies in colorectal cancer patients suggest PDGF over-expression correlates with 
vascular invasion and invasion was significantly greater in patients expressing PDGFBβ at a high 
level.93 Further, patients with high PDGFBβ expression also had a significantly poorer survival 
rate.94 
Firstly, the goal was to see if cell death could be exacerbated with the [2μM curcumin + 
2μM sildenafil + 2μM regorafenib] drug combination. Results indicate that although [curcumin + 
sildenafil] drug combination does attain cell death, the [2μM curcumin + 2μM sildenafil + 2μM 
regorafenib] drug combination achieves significantly greater cell death over a 6, 12, and 24 hour 
period. (Figures 4-6) Cell treatment with [2μM curcumin + 2μM sildenafil + 2μM regorafenib] 
was shown to affect endoplasmic reticulum stress (ER Stress) signaling. ER stress signaling is 
mediated through three self-regulatory pathways: eIF2α, IRE1, and ATF6. Signaling by eIF2α 
reduces transcription from many cyto-protective gene that code for proteins like MCL-1, Bcl-
XL, Erk, AKT and K-Ras resulting in the rapid reduction of protein expression for those with 
short half-lives. The reduced expression of multiple chaperones/cyto-protective proteins as a 
result of using the [2μM curcumin + 2μM sildenafil + 2μM regorafenib] drug combination 
significantly enhanced eIF2α S51 phosphorylation in HT-29, HCT-116 and CT-26 cells. This led 
to an eIF2 dependent dephosphorylation of mTOR and the mTOR substrate ULK1 S757 and 
the phosphorylation of ULK1 S317 which ultimately led to ULK1 activation. ULK1 activation 
resulted in a significant increase in ATG13 S318 phosphorylation and a significant increase in 
Beclin 1 expression. This implies that the [2μM curcumin + 2μM sildenafil + 2μM regorafenib] 
drug combination mediates ER stress, apoptosis and autophagy in the cell. Moreover, the [2μM 
curcumin + 2μM sildenafil + 2μM regorafenib] was not only shown to mediate reduction of 
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mTORC1 and mTORC2 phosphorylation but increase the activity of autophagy proteins e.g. 
Beclin1 and ATG5, indicating a role for eIF2α dependent reduction in expression of many cyto-
protective genes e.g. HSP70, HSP90 and GRP78. (Figures 7-15) Past studies in this lab have 
accurately illustrated autophagy signaling and mitochondrial control of apoptosis.11  
These data indicate that the [2μM curcumin + 2μM sildenafil + 2μM regorafenib] drug 
combination could have a significant effect on killing colorectal cancer cells in vitro. To further 
validate this, transfection of small interfering RNA (siRNA) experiments were completed in 
order to create a holistic idea that will further verify the potency of this drug combination. Prior 
studies done in the Dent laboratory have indicated knockdown of pro-apoptotic and autophagic 
proteins suppress cell death.11 Knockdown of autophagic proteins e.g. (ATG5 and Beclin1) and 
pro-apoptotic proteins (e.g. Noxa, Puma, Bax and Bak) in junction with the [2μM curcumin + 
2μM sildenafil + 2μM regorafenib] drug significantly reduced cell death in the HCT-116 and 
HT-29 colorectal cell lines. After observing the significance of pro-apoptotic proteins, the next 
steps included assessing molecular pathways that deal with ER stress, apoptosis and autophagy 
signaling because, prior to experimentation, there was a significant increase in activity in 
proteins such as ATM, AMPK and eIF2α with the use of the [2μM curcumin + 2μM sildenafil + 
2μM regorafenib] drug. The next step was to see if stable knock down of ATM, AMPK, ULK1, 
CD95, FADD, eIF2α, Perk, AIF, and Cath B to further understand the underlying mechanisms 
effected by the drug combination. After intensive experimentation, knockdown of these proteins 
significantly reduced cell death across the HT-29 and HCT-116 cell lines. This indicates these 
proteins must be active along with the drug in order to achieve lethality. An infection experiment 
was performed with a cytomegalovirus (CMV) to test the effect of [2μM curcumin + 2μM 
sildenafil + 2μM regorafenib] drug treatment on cyto-protective proteins e.g. FLIP, BCL-XL, 
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DN caspase 9, GRP78, and HSP70 when they are upregulated. The reduction of cell death in 
these proteins suggests that they play a significant role in protecting the CRC. (Figures 16-23)  
In addition to reducing the expression of a number of molecular chaperone proteins, 
previous studies in our laboratory have indicated that the induction of autophagy can lead to 
reduced expression of histone deacetylase enzymes (HDACs).20 In this study HT-29, HCT-116 
and CT-26 cells, curcumin and sildenafil plus regorafenib mediated a down regulation of 
HDACs. Histone acetylation and deacetylation is a dynamic process balanced by histone 
acetyltransferase enzymes (HAT) and histone deacetylase enzymes (HDAC). In general, addition 
of acetyl groups to histones via HATs promote gene expression by creating an “open” chromatin 
conformation. Removal of acetyl groups by HDACs results in a “closed” conformation and 
represses transcription. The aim of the study was inhibit HDAC expression so that the tumor 
cells could produce pro-apoptotic proteins via transcription and translation that could activate 
and facilitate cell death. The [2μM curcumin + 2μM sildenafil + 2μM regorafenib] combination 
drug decreased the expression of all HDACs across all three cell lines. This suggests that [2μM 
curcumin + 2μM sildenafil + 2μM regorafenib] drug combination is acting as potent HDAC 
inhibitor, and concurrently inducing increased DNA damage and ultimately inducing apoptosis 
and autophagy. (Figures 24-26)  
One aspect of HDAC down-regulation shown from other studies was that reduced 
expression of HDACs was correlated with altered expression of multiple cellular proteins; 
including alterations in the levels of proteins that could potentially modify the immunogenicity 
of the tumor cells to checkpoint inhibitory immunotherapies 17,18,20. Recent studies have linked 
altered HDAC expression in cancer cells to an altered expression of a number of immunogenic 
biomarkers predicted to enhance tumor cell immunogenicity and to decrease tumor cell 
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viability.20 In the Dent laboratory several model systems, including melanoma and NSCLC were 
used in vitro were confirmed in vivo.11,17,84,97,98   In the present studies, in HCT-116, HT-29 and 
CT-26 cells, [curcumin+ sildenafil+ regorafenib] drug combination rapidly decreased the 
expression of PD-L1, PD-L2, ODC and IDO. The [2μM curcumin + 2μM sildenafil + 2μM 
regorafenib] drug combination used increased the levels of MHCA. This indicates that the cancer 
cells are now being presented as foreign material instead of self-antigens and can be eliminated 
by a person’s own immune system.  (Figures 27-29)  
The next step in this study was to see if the [2μM curcumin + 2μM sildenafil + 2μM 
regorafenib] drug combination had any effect on receptor activity. The main objective was to 
decrease the activity of PDGFRβ, however we also observed the activity of other protein kinases 
as well. They include: ERBB1, ERBB2, ERBB3, Raf-1, and B-Raf. Whenever a receptor 
tyrosine kinase is activated it is phosphorylated on certain residues that lead to a cascade of 
events. In this study, we assessed levels of phosphorylated receptors verses the total amount of 
receptor activity and concluded that the drug combination does have significant effects on 
receptor expression. These findings suggest that receptor tyrosine kinases that aid in cell growth 
and cell proliferation in the HCT-116 and HT-29 colorectal tumor cell lines are halted by the 
[2μM curcumin + 2μM sildenafil + 2μM regorafenib] drug combination and are subsequently 
activating autophagy and apoptosis. (Figures 30-33)  
Since the study had revealed that apoptotic and autophagic proteins were essential to 
achieve cell death, the next objective was to see the level of activity in MCL1, BCL-XL, mToR 
phosphorylation at serine residue 2448 and ATG-13 phosphorylation at serine reside 318 when 
Perk, eIF2α, Beclin, CD95, ATM and AMPK were knocked down via siRNA. The results reveal 
that the cyto-protective proteins MCL1 and BCL-XL were significantly upregulated compared to 
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the scramble vehicle, even in the presence of [2μM curcumin + 2μM sildenafil + 2μM 
regorafenib]. This indicates that in order to achieve cell toxicity, the proteins that were 
knockdown have to be viable and active. There was an apparent decrease in ATG-13 
phosphorylation at protein reside 318 compared to the scramble vehicle which indicative of 
knockdown proteins aiding in the phosphorylation. The data shown for the activity of mToR 
across the HCT-116 and HT-29 cell lines indicates the following: since the AMPK proteins are 
knocked down, there is no sense of energy deprivation or autophagy signaling. As a result, the 
CRC continue to proliferate as a result via activation of mToR. Knockdown of ATM indicates 
there is a loss of the ability to sense DNA breaks which will then lead to the avoidance cell cycle 
checkpoints and the continuation of mutations as well as proliferation. With the CD95 
knockdown, CRC can no longer activate extrinsic apoptosis and CRC cells proliferate. The 
knockdown of Beclin1 suggest the likelihood of autophagy is close to nonexistent and 
knockdown of eIF2α and PERK means that there’s no protein synthesis. Thus, mToR cannot 
cause cells to proliferate because the lack of proteins. (Figures 34-41) When the HT-29 and 
HCT-116 colorectal tumor cells were reprobed with eIF2α antibody to investigate its activity 
with the respective knockdowns, it was apparent that activity was suppressed compared to the 
scramble vehicle. This is indicative to the idea that the activity of eIF2α has be high in order to 
generate pro-apoptotic and autophagic structures to commence cell killing. (Figures 42-43)    
Lastly, an animal study was performed using CT-26 colorectal cancer cells growing in 
their syngeneic C57/BL6 mice. Five days of treatment with the [2μM curcumin + 2μM sildenafil 
+ 2μM regorafenib] drug combination significantly reduced tumor growth rate and continued to 
do so over 25 days compared to the vehicle treated mice. Two administrations of an anti-PD-1 
antibody at days two and four caused a further significant reduction in the rate of tumor growth 
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when the [2μM curcumin + 2μM sildenafil + 2μM regorafenib] drug combination was used, 
whereas administration of the antibody combined with vehicle control had no appreciable effect 
on tumor growth (Figure 44). PDL1 plays a critical role in the maintenance of autoimmunity.85 It 
has also been shown to suppress the adaptive immune system during particular events e.g. tumor 
growth. The binding of PD-L1 to the inhibitory checkpoint molecule PD-1 transmits inhibitory 
signals via immuno-receptor tyrosine-based switch motif (ITSM). This reduces the proliferation 
of antigen-specific T-cells in lymph nodes, while simultaneously reducing T cells’ ability to 
activate apoptosis in tumor cells.96 The findings presented in this manuscript suggest that [2μM 
curcumin + 2μM sildenafil + 2μM regorafenib] drug combination not only has having an effect 
on PD-1/PDL-1 binding affinity but also has some influence on MHCA levels as well. 
During this study, there was a significant upregulation in ERBB3 tyrosine receptor kinase 
in the HT-29 cell line even in the presences of the [2μM curcumin + 2μM sildenafil + 2μM 
regorafenib] drug combination. ERBB3 is closely associated with mutant B-raf. This protein 
plays a role in regulating the MAPK/ERK signaling pathway, which affects cell division and 
differentiation. Mutations in this gene, most commonly occur when valine is substituted with 
glutamic acid at amino acid position 600 in a protein (V600E mutation). This mutation is most 
frequently identified in melanoma and other cancers, including non-Hodgkin lymphoma, 
colorectal cancer, thyroid carcinoma, non-small cell lung carcinoma, hairy cell leukemia and 
adenocarcinoma of lungs.97 Drugs that treat cancers driven by B-raf mutations have been 
developed. Two of these drugs, vemurafenib and dabrafenib, are approved by the FDA for 
treatment of late-stage melanoma. Vemurafenib was the first drug to come out of fragment-based 
drug discovery.97 The next logical step in treating upregulated ERBB3 in the HT-29 colorectal 
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tumor cell line is to use dabrafenib with sildenafil and curcumin to see if there would be any 
significant effect.     
Studies performed outside of the Dent lab suggest that curcumin in the perfect candidate 
for treatment of colorectal cancers. Specifically, curcumin has been previously reported to alter 
AMPK, Akt, and Ulk-1 levels significantly by adding cytotoxicity to cells.99 There have also 
been reports of treating colorectal cancer stem cells with curcumin by heightening their 
chemosensitivity to chemotherapeutic treatment, thus markedly increasing positive therapeutic 
outcome, especially on cell lines used in this study (e.g. HCT-116 tumor cells).100 Many studies 
have reported curcumin interacting with other drugs in an additive fashion to kill colorectal 
cancer cells. Drugs such as dasatinib, 5-fluorouracil, irinotecan which are used for chronic 
myelogenous leukemia (CML), breast and pancreatic cancers and a topoisomerase-1 inhibition 
respectively along with curcumin have enhanced lethality.74,99,101,102 The approach for this study 
in particular has taken similar steps with the use of curcumin and its ability to halt proliferation 
and increase drug interactions. The key difference is that, in the current study, sildenafil and 
regorafenib were utilized. Moreover, the data presented in this study suggest that the [sildenafil + 
curcumin + regorafenib] drug combination is a very good for targeted therapy. It is understood 
that resistance to targeted drug combination therapy in colorectal cancer cells can and does 
ultimately happen. For example, the pervious study performed in the Dent lab determined that 
cells that were isolated from in vivo treated [curcumin + sildenafil] tumors became resistant in 
vitro.11 To combat the resistance, regorafenib were added to induce cell death.  
 Previous reports state the clinical relevance of regorafenib. For example, treatment with 
regorafenib resulted in a significant improvement of overall survival.103 A clinical trial showed 
the efficacy of regorafenib during phase III of colorectal cancer after failure of standard 
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therapy.104 There are also findings that include regorafenib working in tandem with other target 
therapy drugs such as cetuximab.105 Cetuximab is an epidermal growth factor receptor (EGFR) 
inhibitor used for the treatment of metastatic colorectal cancer. The efficacy of cetuximab against 
EGFR was lowered due to tumor cell resistance. However, the combined treatment with 
cetuximab and regorafenib induced synergistic anti-proliferative and apoptotic effects which 
caused significant tumor growth inhibition.105 The cetuximab/regorafenib study not only 
provides a rationale for the use of drug combination therapy but it gives rise to the idea that 
preventing and/or overcoming colorectal cancer drug resistance in patients has practical 
reasoning. Hence the reason why regorafenib was added to the study: to lower tumor cell 
resistance. Overall, the data in this report suggest that the [2μM curcumin + 2μM sildenafil + 
2μM regorafenib] drug combination is a great choice for a mechanistic cell killing.  
In terms of the future direction of this study, the Dent laboratory will have to look into 
the proto-oncogene tyrosine-protein kinase Src. Src is short for sarcoma and is responsible for 
phosphorylating certain tyrosine residues on other proteins. More specifically, there are two 
major phosphorylation sites on Src: one is at tyrosine 416 (or Y416), the other at tyrosine 527 
(Y527).95 The Dent laboratory should turn their attention to the activity of Src by look at these 
phosphorylation sites. The animal studies have successful results and the next step is to promote 
clinical trials on human so far as the [2μM curcumin + 2μM sildenafil + 2μM regorafenib] drug 
combination are given at clinically suitable levels. More experimentation on different types of 
colorectal cancer cell lines is also need to see how far the [2μM curcumin + 2μM sildenafil + 
2μM regorafenib] drug combination can go in treatment. 
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Figure 45. Curcumin, sildenafil and regorafenib drug combination interact synergistically 
to kill colorectal tumor cells11 
 
Exposure to [2μM curcumin + 2μM sildenafil + 2μM regorafenib] increases reactive oxygen 
species (ROS) and reactive nitrogen species (RNS) in colorectal tumor cells that induces DNA 
damage and inactivates chaperone proteins. This, in turn, inactivates cyto-protective proteins and 
increases apoptotic. Concurrently, DNA damage increases the activity of AMPK, deactivates 
mToR, and activates ATG13 which then stimulates autophagosome production. The [2μM 
curcumin + 2μM sildenafil + 2μM regorafenib] drug combination increases cytotoxicity which in 
turn activates CD95 and ultimately leads to cell death. 
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Conclusion 
 
To conclude, this study demonstrated that curcumin and sildenafil work alongside the 
multi-kinase inhibitor regorafenib as a potent targeted therapy treatment. This drug combination 
effectively killed colorectal cancer cells in vitro as well as in vivo in mice via stimulating 
endoplasmic reticulum stress and increasing reactive oxygen/nitrogen species. These processes 
ultimately led to autophagosome and autophagolysosome formation and apoptosis.     
 
 
 
 
 
 
. 
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